lixisenatide vs Semaglutide (Rybelsus)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline

lixisenatide · Adlyxin / Lyxumia

Marketed by Sanofi and partners

Approved in Type 2 Diabetespeptide
Partial signal

NCT00707031 · Phase 3 · completed

The 639 participants were randomly assigned to lixisenatide or active treatment with exenatide, but the study was not blinded. The primary HbA1c comparison met its prespecified non-inferiority criterion, with a between-group difference of 0.17 percentage points and a 95% confidence interval of 0.033 to 0.297, but HbA1c is a surrogate endpoint rather than a hard clinical outcome.

Next expected readout: June 2027 · NCT07173712 (registry estimate)

Reported efficacy

Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Lixisenatide -0.79 percentage of hemoglobin (Standard Error 0.053) vs Exenatide -0.96 percentage of hemoglobin (Standard Error 0.054) (met)

Result source: NCT00707031

Semaglutide (Rybelsus)

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: January 2027 · NCT06050577 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointlixisenatideSemaglutide (Rybelsus)
HbA1c, change-0.6% vs 0.1%−0.6 vs placebowk 24 · n 172NCT01798706
19 other results
  • -0.8% vs -0.5% wk 24 · n 185 · Phase 3 · primary NCT01169779
  • -0.7% vs -0.4% wk 24 · n 215 · Phase 3 · primary NCT00975286
  • -0.9% vs -0.3% wk 24 · n 308 · Phase 3 · primary NCT00763815
  • -0.7% vs -0.4% wk 24 · n 304 · Phase 3 · primary NCT00715624
  • -0.8% vs -0.1% wk 24 · n 544 · Phase 3 · primary NCT00713830
  • -0.8% vs -0.4% wk 24 · n 152 · Phase 3 · primary NCT00763451
  • -0.9% vs -0.4% wk 24 · n 156 · Phase 3 · primary NCT00763451
  • -0.8% vs 0.1% wk 24 · n 146 · Phase 3 · primary NCT00866658
  • -0.6% vs -0.8% wk 26 · n 292 · Phase 3 · primary NCT01768559
  • -0.8% vs -1.0% wk 24 · n 295 · Phase 3 · primary NCT00707031
  • -1.9% vs -1.7% wk 24 · n 291 · Phase 3 · primary NCT05413369
  • -1.1% vs -0.6% wk 30 · n 364 · Phase 3 · primary NCT02058160
  • -1.6% vs -1.3% wk 30 · n 467 · Phase 3 · primary NCT02058147
  • -0.8% vs -1.3% wk 30 · n 233 · Phase 3 · primary NCT02058147
  • -1.9% vs -1.7% wk 24 · n 291 · Phase 3 · secondary NCT05413369
  • -0.7% vs -0.7% wk 24 · n 150 · Phase 3 · secondary NCT00976937
  • -1.8% vs -1.6% wk 24 · n 160 · Phase 2 · primary NCT01476475
  • -0.6% vs -0.7% 20 µg · wk 8 · n 46 · Phase 2 · secondary NCT01596504
  • -0.3% vs -0.5% wk 4 · n 75 · Phase 2 · secondary NCT01175473
-1.6% vs -0.2%−1.4 vs placebo14 mg · wk 26 · n 116NCT04109547
34 other results
  • -1.5% vs -0.2% 7 mg · wk 26 · n 117 · Phase 3 · primary NCT04109547
  • -1.1% vs -0.2% 3 mg · wk 26 · n 114 · Phase 3 · primary NCT04109547
  • -0.7% vs -0.1% wk 104 · n 4076 · Phase 3 · secondary NCT03914326
  • -1% vs -0.3% n 1489 · Phase 3 · secondary NCT02692716
  • -1.2% vs -0.1% 14 mg · wk 52 · n 275 · Phase 3 · secondary NCT02863419
  • -1.2% vs -0.2% 14 mg · wk 52 · n 168 · Phase 3 · secondary NCT03021187
  • -0.9% vs -0.2% 7 mg · wk 52 · n 169 · Phase 3 · secondary NCT03021187
  • -0.6% vs -0.2% 3 mg · wk 52 · n 173 · Phase 3 · secondary NCT03021187
  • -1.5% vs 0.1% 14 mg · wk 52 · n 41 · Phase 3 · secondary NCT03018028
  • -1.4% vs 0.1% 7 mg · wk 52 · n 43 · Phase 3 · secondary NCT03018028
  • -1% vs 0.1% 3 mg · wk 52 · n 38 · Phase 3 · secondary NCT03018028
  • -2% vs -1.6% 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -1.3% vs -0.9% 14 mg · wk 52 · n 384 · Phase 3 · secondary NCT02863328
  • -1.2% vs -0.7% 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -1.1% vs -0.7% 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -1% vs -0.7% 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -0.9% vs -0.7% 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -0.6% vs -0.7% 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -0.6% vs -0.7% 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -1.8% vs -1.4% 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -1.7% vs -1.6% 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • -1.4% vs -1.4% 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -1.1% vs -1.6% 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • -0.8% vs -1.4% 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -1.3% vs -0.8% wk 52 · n 230 · Phase 3 · secondary NCT02849080
  • -0.2% vs 0% wk 104 · n 92 · Phase 3 · secondary NCT02849080
  • -2.0% vs -0.4% 40 mg · wk 26 · n 46 · Phase 2 · primary NCT01923181
  • -1.8% vs -0.4% 40 mg · wk 26 · n 52 · Phase 2 · primary NCT01923181
  • -1.6% vs -0.4% 40 mg · wk 26 · n 44 · Phase 2 · primary NCT01923181
  • -1.7% vs -0.4% 20 mg · wk 26 · n 48 · Phase 2 · primary NCT01923181
  • -1.6% vs -0.4% 10 mg · wk 26 · n 57 · Phase 2 · primary NCT01923181
  • -1.2% vs -0.4% 5 mg · wk 26 · n 58 · Phase 2 · primary NCT01923181
  • -0.9% vs -0.4% 2.5 mg · wk 26 · n 56 · Phase 2 · primary NCT01923181
  • -1.2% vs -1.0% wk 52 · n 326 · Phase 4 · primary NCT05035082
Body weight, change (kg)-0.6 vs 1.0vs Insulin Glulisinewk 26 · n 295NCT01768559
17 other results
  • -1.5 vs -0.2 wk 24 · n 174 · Phase 3 · secondary NCT01798706
  • -1.5 vs -1.2 wk 24 · n 188 · Phase 3 · secondary NCT01169779
  • 0.3 vs 1.2 wk 24 · n 217 · Phase 3 · secondary NCT00975286
  • -0.2 vs 0.2 wk 24 · n 315 · Phase 3 · secondary NCT00763815
  • -1.8 vs -0.5 wk 24 · n 311 · Phase 3 · secondary NCT00715624
  • -1.8 vs -0.9 wk 24 · n 554 · Phase 3 · secondary NCT00713830
  • -2.7 vs -1.6 wk 24 · n 155 · Phase 3 · secondary NCT00763451
  • -2.6 vs -1.6 wk 24 · n 158 · Phase 3 · secondary NCT00763451
  • -0.4 vs 0.1 wk 24 · n 150 · Phase 3 · secondary NCT00866658
  • -3.0 vs -4.0 wk 24 · n 295 · Phase 3 · secondary NCT00707031
  • -0.3 vs 1.2 wk 24 · n 291 · Phase 3 · secondary NCT05413369
  • -0.7 vs 0.7 wk 30 · n 365 · Phase 3 · secondary NCT02058160
  • -0.3 vs 1.1 wk 30 · n 467 · Phase 3 · secondary NCT02058147
  • -2.5 vs -1.2 wk 24 · n 152 · Phase 3 · secondary NCT00976937
  • -2.3 vs 1.1 wk 30 · n 233 · Phase 3 · secondary NCT02058147
  • -1.0 vs 0.5 wk 24 · n 159 · Phase 2 · secondary NCT01476475
  • -1.6 vs -2.4 20 µg · wk 8 · n 46 · Phase 2 · secondary NCT01596504
-4.2 vs -1.3−2.9 vs placebowk 104 · n 4251NCT03914326
39 other results
  • -4.2 vs -0.8 n 1510 · Phase 3 · secondary NCT02692716
  • -3.1 vs -1.1 14 mg · wk 26 · n 116 · Phase 3 · secondary NCT04109547
  • -4.4 vs -1 14 mg · wk 52 · n 275 · Phase 3 · secondary NCT02863419
  • -3.8 vs 0.5 14 mg · wk 52 · n 170 · Phase 3 · secondary NCT03021187
  • -2.4 vs -1.1 14 mg · wk 26 · n 48 · Phase 3 · secondary NCT03018028
  • -2.9 vs -1 14 mg · wk 52 · n 48 · Phase 3 · secondary NCT03018028
  • -2.2 vs -1.1 7 mg · wk 26 · n 119 · Phase 3 · secondary NCT04109547
  • -2.2 vs 0.5 7 mg · wk 52 · n 171 · Phase 3 · secondary NCT03021187
  • -1.1 vs -1.1 3 mg · wk 26 · n 115 · Phase 3 · secondary NCT04109547
  • -0.9 vs 0.5 3 mg · wk 52 · n 174 · Phase 3 · secondary NCT03021187
  • -1.2 vs -1.1 7 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -0.8 vs -1 7 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -0.4 vs -1.1 3 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • 0 vs -1 3 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -3.8 vs -0.5 14 mg · wk 26 · n 300 · Phase 3 · secondary NCT04017832
  • -4 vs -3.7 14 mg · wk 52 · n 386 · Phase 3 · secondary NCT02863328
  • -3.5 vs -0.7 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -3.2 vs -1 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -2.9 vs -0.5 7 mg · wk 26 · n 319 · Phase 3 · secondary NCT04017832
  • -2.5 vs -0.7 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -2.8 vs -1 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -2.2 vs 0.3 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -1.7 vs 1 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -0.9 vs 1 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -1.4 vs -0.5 3 mg · wk 26 · n 322 · Phase 3 · secondary NCT04017832
  • -1.6 vs -0.7 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -1.8 vs -1 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -1 vs 0.3 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • -0.1 vs 0.3 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • 0 vs 1 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -2.6 vs -0.9 wk 104 · n 93 · Phase 3 · secondary NCT02849080
  • -6.9 vs -1.2 40 mg · wk 26 · n 46 · Phase 2 · secondary NCT01923181
  • -5.9 vs -1.2 40 mg · wk 26 · n 51 · Phase 2 · secondary NCT01923181
  • -8.3 vs -1.2 40 mg · wk 26 · n 44 · Phase 2 · secondary NCT01923181
  • -5.8 vs -1.2 20 mg · wk 26 · n 47 · Phase 2 · secondary NCT01923181
  • -4.9 vs -1.2 10 mg · wk 26 · n 57 · Phase 2 · secondary NCT01923181
  • -2.9 vs -1.2 5 mg · wk 26 · n 57 · Phase 2 · secondary NCT01923181
  • -2.0 vs -1.2 2.5 mg · wk 26 · n 56 · Phase 2 · secondary NCT01923181
  • -3.9 vs -3.5 wk 52 · n 290 · Phase 4 · secondary NCT05035082
HbA1c below 7%53% vs 38.8%+14.2 vs placebowk 24 · n 185NCT01169779
10 other results
  • 56.3% vs 38.5% wk 24 · n 215 · Phase 3 · secondary NCT00975286
  • 52.3% vs 26.4% wk 24 · n 308 · Phase 3 · secondary NCT00763815
  • 28.3% vs 12% wk 24 · n 304 · Phase 3 · secondary NCT00715624
  • 36.4% vs 13.5% wk 24 · n 544 · Phase 3 · secondary NCT00713830
  • 42.1% vs 24.1% wk 24 · n 152 · Phase 3 · secondary NCT00763451
  • 47.4% vs 24.1% wk 24 · n 156 · Phase 3 · secondary NCT00763451
  • 35.6% vs 5.2% wk 24 · n 146 · Phase 3 · secondary NCT00866658
  • 48.5% vs 49.8% wk 24 · n 295 · Phase 3 · secondary NCT00707031
  • 72.5% vs 59.8% wk 24 · n 291 · Phase 3 · secondary NCT05413369
  • 40.7% vs 40% wk 24 · n 150 · Phase 3 · secondary NCT00976937
—Not posted · NCT07271251
Fasting plasma glucose, change-0.3 vs 0.0−0.3 vs placebowk 24 · n 171NCT01798706
17 other results
  • -0.7 vs -0.2 wk 24 · n 190 · Phase 3 · secondary NCT01169779
  • 0.3 vs 0.5 wk 24 · n 214 · Phase 3 · secondary NCT00975286
  • -1.2 vs -0.3 wk 24 · n 317 · Phase 3 · secondary NCT00763815
  • -0.6 vs -0.6 wk 24 · n 317 · Phase 3 · secondary NCT00715624
  • -1.0 vs -0.4 wk 24 · n 564 · Phase 3 · secondary NCT00713830
  • -0.6 vs 0.1 wk 24 · n 160 · Phase 3 · secondary NCT00763451
  • -0.5 vs 0.1 wk 24 · n 158 · Phase 3 · secondary NCT00763451
  • -0.4 vs 0.3 wk 24 · n 148 · Phase 3 · secondary NCT00866658
  • -0.2 vs -0.2 wk 26 · n 295 · Phase 3 · secondary NCT01768559
  • -1.2 vs -1.4 wk 24 · n 310 · Phase 3 · secondary NCT00707031
  • -3.2 vs -3.5 wk 24 · n 291 · Phase 3 · secondary NCT05413369
  • -0.3 vs -0.5 wk 30 · n 364 · Phase 3 · secondary NCT02058160
  • -3.5 vs -3.3 wk 30 · n 465 · Phase 3 · secondary NCT02058147
  • -0.5 vs -0.7 wk 24 · n 153 · Phase 3 · secondary NCT00976937
  • -1.5 vs -3.3 wk 30 · n 232 · Phase 3 · secondary NCT02058147
  • -3.4 vs -3.5 wk 24 · n 159 · Phase 2 · secondary NCT01476475
  • 0.1 vs 0.1 20 µg · wk 8 · n 45 · Phase 2 · secondary NCT01596504
-1.9 vs -0.2−1.7 vs placebo14 mg · wk 26 · n 160NCT02906930
39 other results
  • -2.0 vs -0.3 14 mg · wk 26 · n 285 · Phase 3 · secondary NCT02863419
  • -1.6 vs -0.3 14 mg · wk 26 · n 151 · Phase 3 · secondary NCT02827708
  • -1.4 vs 0.5 14 mg · wk 26 · n 181 · Phase 3 · secondary NCT03021187
  • -1.9 vs -0.7 14 mg · wk 52 · n 285 · Phase 3 · secondary NCT02863419
  • -1.6 vs -0.1 14 mg · wk 52 · n 181 · Phase 3 · secondary NCT03021187
  • -1.5 vs -0.2 7 mg · wk 26 · n 160 · Phase 3 · secondary NCT02906930
  • -1.1 vs 0.5 7 mg · wk 26 · n 182 · Phase 3 · secondary NCT03021187
  • -1.1 vs -0.1 7 mg · wk 52 · n 182 · Phase 3 · secondary NCT03021187
  • -0.9 vs -0.2 3 mg · wk 26 · n 166 · Phase 3 · secondary NCT02906930
  • -0.5 vs 0.5 3 mg · wk 26 · n 184 · Phase 3 · secondary NCT03021187
  • -0.8 vs -0.1 3 mg · wk 52 · n 184 · Phase 3 · secondary NCT03021187
  • -2.4 vs -0.4 14 mg · wk 26 · n 48 · Phase 3 · secondary NCT03018028
  • -2.3 vs 0.3 14 mg · wk 52 · n 48 · Phase 3 · secondary NCT03018028
  • -1.6 vs -0.4 7 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -1.6 vs 0.3 7 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -1.6 vs -0.4 3 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -1.1 vs 0.3 3 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -2.0 vs -2.1 14 mg · wk 26 · n 411 · Phase 3 · secondary NCT02863328
  • -1.7 vs -0.9 14 mg · wk 26 · n 465 · Phase 3 · secondary NCT02607865
  • -2 vs -0.5 14 mg · wk 26 · n 294 · Phase 3 · secondary NCT04017832
  • -2.0 vs -2.1 14 mg · wk 52 · n 411 · Phase 3 · secondary NCT02863328
  • -1.8 vs -1.0 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -1.6 vs -0.9 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -1.2 vs -0.9 7 mg · wk 26 · n 465 · Phase 3 · secondary NCT02607865
  • -1.8 vs -0.5 7 mg · wk 26 · n 317 · Phase 3 · secondary NCT04017832
  • -1.3 vs -1.0 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -1.1 vs -0.9 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -0.8 vs -0.9 3 mg · wk 26 · n 466 · Phase 3 · secondary NCT02607865
  • -2.2 vs -1.8 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -2.0 vs -1.8 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -1.0 vs -0.5 3 mg · wk 26 · n 322 · Phase 3 · secondary NCT04017832
  • -1.0 vs -1.0 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -1.1 vs -0.9 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -2.7 vs -2.2 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -2.3 vs -2.2 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • -1.2 vs -2.2 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • -0.9 vs -1.8 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -2.4 vs -1.4 wk 52 · n 229 · Phase 3 · secondary NCT02849080
  • -0.3 vs 0.0 wk 104 · n 92 · Phase 3 · secondary NCT02849080
3-point MACE (% with event)—Not reported12% vs 13.8%−1.8 vs placebowk 265 · n 4825NCT03914326
1 other result

HbA1c, change

lixisenatide
-0.6% vs 0.1%−0.6 vs placebowk 24 · n 172NCT01798706
19 other results
  • -0.8% vs -0.5% wk 24 · n 185 · Phase 3 · primary NCT01169779
  • -0.7% vs -0.4% wk 24 · n 215 · Phase 3 · primary NCT00975286
  • -0.9% vs -0.3% wk 24 · n 308 · Phase 3 · primary NCT00763815
  • -0.7% vs -0.4% wk 24 · n 304 · Phase 3 · primary NCT00715624
  • -0.8% vs -0.1% wk 24 · n 544 · Phase 3 · primary NCT00713830
  • -0.8% vs -0.4% wk 24 · n 152 · Phase 3 · primary NCT00763451
  • -0.9% vs -0.4% wk 24 · n 156 · Phase 3 · primary NCT00763451
  • -0.8% vs 0.1% wk 24 · n 146 · Phase 3 · primary NCT00866658
  • -0.6% vs -0.8% wk 26 · n 292 · Phase 3 · primary NCT01768559
  • -0.8% vs -1.0% wk 24 · n 295 · Phase 3 · primary NCT00707031
  • -1.9% vs -1.7% wk 24 · n 291 · Phase 3 · primary NCT05413369
  • -1.1% vs -0.6% wk 30 · n 364 · Phase 3 · primary NCT02058160
  • -1.6% vs -1.3% wk 30 · n 467 · Phase 3 · primary NCT02058147
  • -0.8% vs -1.3% wk 30 · n 233 · Phase 3 · primary NCT02058147
  • -1.9% vs -1.7% wk 24 · n 291 · Phase 3 · secondary NCT05413369
  • -0.7% vs -0.7% wk 24 · n 150 · Phase 3 · secondary NCT00976937
  • -1.8% vs -1.6% wk 24 · n 160 · Phase 2 · primary NCT01476475
  • -0.6% vs -0.7% 20 µg · wk 8 · n 46 · Phase 2 · secondary NCT01596504
  • -0.3% vs -0.5% wk 4 · n 75 · Phase 2 · secondary NCT01175473
Semaglutide (Rybelsus)
-1.6% vs -0.2%−1.4 vs placebo14 mg · wk 26 · n 116NCT04109547
34 other results
  • -1.5% vs -0.2% 7 mg · wk 26 · n 117 · Phase 3 · primary NCT04109547
  • -1.1% vs -0.2% 3 mg · wk 26 · n 114 · Phase 3 · primary NCT04109547
  • -0.7% vs -0.1% wk 104 · n 4076 · Phase 3 · secondary NCT03914326
  • -1% vs -0.3% n 1489 · Phase 3 · secondary NCT02692716
  • -1.2% vs -0.1% 14 mg · wk 52 · n 275 · Phase 3 · secondary NCT02863419
  • -1.2% vs -0.2% 14 mg · wk 52 · n 168 · Phase 3 · secondary NCT03021187
  • -0.9% vs -0.2% 7 mg · wk 52 · n 169 · Phase 3 · secondary NCT03021187
  • -0.6% vs -0.2% 3 mg · wk 52 · n 173 · Phase 3 · secondary NCT03021187
  • -1.5% vs 0.1% 14 mg · wk 52 · n 41 · Phase 3 · secondary NCT03018028
  • -1.4% vs 0.1% 7 mg · wk 52 · n 43 · Phase 3 · secondary NCT03018028
  • -1% vs 0.1% 3 mg · wk 52 · n 38 · Phase 3 · secondary NCT03018028
  • -2% vs -1.6% 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -1.3% vs -0.9% 14 mg · wk 52 · n 384 · Phase 3 · secondary NCT02863328
  • -1.2% vs -0.7% 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -1.1% vs -0.7% 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -1% vs -0.7% 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -0.9% vs -0.7% 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -0.6% vs -0.7% 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -0.6% vs -0.7% 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -1.8% vs -1.4% 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -1.7% vs -1.6% 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • -1.4% vs -1.4% 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -1.1% vs -1.6% 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • -0.8% vs -1.4% 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -1.3% vs -0.8% wk 52 · n 230 · Phase 3 · secondary NCT02849080
  • -0.2% vs 0% wk 104 · n 92 · Phase 3 · secondary NCT02849080
  • -2.0% vs -0.4% 40 mg · wk 26 · n 46 · Phase 2 · primary NCT01923181
  • -1.8% vs -0.4% 40 mg · wk 26 · n 52 · Phase 2 · primary NCT01923181
  • -1.6% vs -0.4% 40 mg · wk 26 · n 44 · Phase 2 · primary NCT01923181
  • -1.7% vs -0.4% 20 mg · wk 26 · n 48 · Phase 2 · primary NCT01923181
  • -1.6% vs -0.4% 10 mg · wk 26 · n 57 · Phase 2 · primary NCT01923181
  • -1.2% vs -0.4% 5 mg · wk 26 · n 58 · Phase 2 · primary NCT01923181
  • -0.9% vs -0.4% 2.5 mg · wk 26 · n 56 · Phase 2 · primary NCT01923181
  • -1.2% vs -1.0% wk 52 · n 326 · Phase 4 · primary NCT05035082

Body weight, change (kg)

lixisenatide
-0.6 vs 1.0vs Insulin Glulisinewk 26 · n 295NCT01768559
17 other results
  • -1.5 vs -0.2 wk 24 · n 174 · Phase 3 · secondary NCT01798706
  • -1.5 vs -1.2 wk 24 · n 188 · Phase 3 · secondary NCT01169779
  • 0.3 vs 1.2 wk 24 · n 217 · Phase 3 · secondary NCT00975286
  • -0.2 vs 0.2 wk 24 · n 315 · Phase 3 · secondary NCT00763815
  • -1.8 vs -0.5 wk 24 · n 311 · Phase 3 · secondary NCT00715624
  • -1.8 vs -0.9 wk 24 · n 554 · Phase 3 · secondary NCT00713830
  • -2.7 vs -1.6 wk 24 · n 155 · Phase 3 · secondary NCT00763451
  • -2.6 vs -1.6 wk 24 · n 158 · Phase 3 · secondary NCT00763451
  • -0.4 vs 0.1 wk 24 · n 150 · Phase 3 · secondary NCT00866658
  • -3.0 vs -4.0 wk 24 · n 295 · Phase 3 · secondary NCT00707031
  • -0.3 vs 1.2 wk 24 · n 291 · Phase 3 · secondary NCT05413369
  • -0.7 vs 0.7 wk 30 · n 365 · Phase 3 · secondary NCT02058160
  • -0.3 vs 1.1 wk 30 · n 467 · Phase 3 · secondary NCT02058147
  • -2.5 vs -1.2 wk 24 · n 152 · Phase 3 · secondary NCT00976937
  • -2.3 vs 1.1 wk 30 · n 233 · Phase 3 · secondary NCT02058147
  • -1.0 vs 0.5 wk 24 · n 159 · Phase 2 · secondary NCT01476475
  • -1.6 vs -2.4 20 µg · wk 8 · n 46 · Phase 2 · secondary NCT01596504
Semaglutide (Rybelsus)
-4.2 vs -1.3−2.9 vs placebowk 104 · n 4251NCT03914326
39 other results
  • -4.2 vs -0.8 n 1510 · Phase 3 · secondary NCT02692716
  • -3.1 vs -1.1 14 mg · wk 26 · n 116 · Phase 3 · secondary NCT04109547
  • -4.4 vs -1 14 mg · wk 52 · n 275 · Phase 3 · secondary NCT02863419
  • -3.8 vs 0.5 14 mg · wk 52 · n 170 · Phase 3 · secondary NCT03021187
  • -2.4 vs -1.1 14 mg · wk 26 · n 48 · Phase 3 · secondary NCT03018028
  • -2.9 vs -1 14 mg · wk 52 · n 48 · Phase 3 · secondary NCT03018028
  • -2.2 vs -1.1 7 mg · wk 26 · n 119 · Phase 3 · secondary NCT04109547
  • -2.2 vs 0.5 7 mg · wk 52 · n 171 · Phase 3 · secondary NCT03021187
  • -1.1 vs -1.1 3 mg · wk 26 · n 115 · Phase 3 · secondary NCT04109547
  • -0.9 vs 0.5 3 mg · wk 52 · n 174 · Phase 3 · secondary NCT03021187
  • -1.2 vs -1.1 7 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -0.8 vs -1 7 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -0.4 vs -1.1 3 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • 0 vs -1 3 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -3.8 vs -0.5 14 mg · wk 26 · n 300 · Phase 3 · secondary NCT04017832
  • -4 vs -3.7 14 mg · wk 52 · n 386 · Phase 3 · secondary NCT02863328
  • -3.5 vs -0.7 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -3.2 vs -1 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -2.9 vs -0.5 7 mg · wk 26 · n 319 · Phase 3 · secondary NCT04017832
  • -2.5 vs -0.7 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -2.8 vs -1 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -2.2 vs 0.3 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -1.7 vs 1 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -0.9 vs 1 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -1.4 vs -0.5 3 mg · wk 26 · n 322 · Phase 3 · secondary NCT04017832
  • -1.6 vs -0.7 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -1.8 vs -1 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -1 vs 0.3 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • -0.1 vs 0.3 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • 0 vs 1 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -2.6 vs -0.9 wk 104 · n 93 · Phase 3 · secondary NCT02849080
  • -6.9 vs -1.2 40 mg · wk 26 · n 46 · Phase 2 · secondary NCT01923181
  • -5.9 vs -1.2 40 mg · wk 26 · n 51 · Phase 2 · secondary NCT01923181
  • -8.3 vs -1.2 40 mg · wk 26 · n 44 · Phase 2 · secondary NCT01923181
  • -5.8 vs -1.2 20 mg · wk 26 · n 47 · Phase 2 · secondary NCT01923181
  • -4.9 vs -1.2 10 mg · wk 26 · n 57 · Phase 2 · secondary NCT01923181
  • -2.9 vs -1.2 5 mg · wk 26 · n 57 · Phase 2 · secondary NCT01923181
  • -2.0 vs -1.2 2.5 mg · wk 26 · n 56 · Phase 2 · secondary NCT01923181
  • -3.9 vs -3.5 wk 52 · n 290 · Phase 4 · secondary NCT05035082

HbA1c below 7%

lixisenatide
53% vs 38.8%+14.2 vs placebowk 24 · n 185NCT01169779
10 other results
  • 56.3% vs 38.5% wk 24 · n 215 · Phase 3 · secondary NCT00975286
  • 52.3% vs 26.4% wk 24 · n 308 · Phase 3 · secondary NCT00763815
  • 28.3% vs 12% wk 24 · n 304 · Phase 3 · secondary NCT00715624
  • 36.4% vs 13.5% wk 24 · n 544 · Phase 3 · secondary NCT00713830
  • 42.1% vs 24.1% wk 24 · n 152 · Phase 3 · secondary NCT00763451
  • 47.4% vs 24.1% wk 24 · n 156 · Phase 3 · secondary NCT00763451
  • 35.6% vs 5.2% wk 24 · n 146 · Phase 3 · secondary NCT00866658
  • 48.5% vs 49.8% wk 24 · n 295 · Phase 3 · secondary NCT00707031
  • 72.5% vs 59.8% wk 24 · n 291 · Phase 3 · secondary NCT05413369
  • 40.7% vs 40% wk 24 · n 150 · Phase 3 · secondary NCT00976937
Semaglutide (Rybelsus)
—Not posted · NCT07271251

Fasting plasma glucose, change

lixisenatide
-0.3 vs 0.0−0.3 vs placebowk 24 · n 171NCT01798706
17 other results
  • -0.7 vs -0.2 wk 24 · n 190 · Phase 3 · secondary NCT01169779
  • 0.3 vs 0.5 wk 24 · n 214 · Phase 3 · secondary NCT00975286
  • -1.2 vs -0.3 wk 24 · n 317 · Phase 3 · secondary NCT00763815
  • -0.6 vs -0.6 wk 24 · n 317 · Phase 3 · secondary NCT00715624
  • -1.0 vs -0.4 wk 24 · n 564 · Phase 3 · secondary NCT00713830
  • -0.6 vs 0.1 wk 24 · n 160 · Phase 3 · secondary NCT00763451
  • -0.5 vs 0.1 wk 24 · n 158 · Phase 3 · secondary NCT00763451
  • -0.4 vs 0.3 wk 24 · n 148 · Phase 3 · secondary NCT00866658
  • -0.2 vs -0.2 wk 26 · n 295 · Phase 3 · secondary NCT01768559
  • -1.2 vs -1.4 wk 24 · n 310 · Phase 3 · secondary NCT00707031
  • -3.2 vs -3.5 wk 24 · n 291 · Phase 3 · secondary NCT05413369
  • -0.3 vs -0.5 wk 30 · n 364 · Phase 3 · secondary NCT02058160
  • -3.5 vs -3.3 wk 30 · n 465 · Phase 3 · secondary NCT02058147
  • -0.5 vs -0.7 wk 24 · n 153 · Phase 3 · secondary NCT00976937
  • -1.5 vs -3.3 wk 30 · n 232 · Phase 3 · secondary NCT02058147
  • -3.4 vs -3.5 wk 24 · n 159 · Phase 2 · secondary NCT01476475
  • 0.1 vs 0.1 20 µg · wk 8 · n 45 · Phase 2 · secondary NCT01596504
Semaglutide (Rybelsus)
-1.9 vs -0.2−1.7 vs placebo14 mg · wk 26 · n 160NCT02906930
39 other results
  • -2.0 vs -0.3 14 mg · wk 26 · n 285 · Phase 3 · secondary NCT02863419
  • -1.6 vs -0.3 14 mg · wk 26 · n 151 · Phase 3 · secondary NCT02827708
  • -1.4 vs 0.5 14 mg · wk 26 · n 181 · Phase 3 · secondary NCT03021187
  • -1.9 vs -0.7 14 mg · wk 52 · n 285 · Phase 3 · secondary NCT02863419
  • -1.6 vs -0.1 14 mg · wk 52 · n 181 · Phase 3 · secondary NCT03021187
  • -1.5 vs -0.2 7 mg · wk 26 · n 160 · Phase 3 · secondary NCT02906930
  • -1.1 vs 0.5 7 mg · wk 26 · n 182 · Phase 3 · secondary NCT03021187
  • -1.1 vs -0.1 7 mg · wk 52 · n 182 · Phase 3 · secondary NCT03021187
  • -0.9 vs -0.2 3 mg · wk 26 · n 166 · Phase 3 · secondary NCT02906930
  • -0.5 vs 0.5 3 mg · wk 26 · n 184 · Phase 3 · secondary NCT03021187
  • -0.8 vs -0.1 3 mg · wk 52 · n 184 · Phase 3 · secondary NCT03021187
  • -2.4 vs -0.4 14 mg · wk 26 · n 48 · Phase 3 · secondary NCT03018028
  • -2.3 vs 0.3 14 mg · wk 52 · n 48 · Phase 3 · secondary NCT03018028
  • -1.6 vs -0.4 7 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -1.6 vs 0.3 7 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -1.6 vs -0.4 3 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -1.1 vs 0.3 3 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -2.0 vs -2.1 14 mg · wk 26 · n 411 · Phase 3 · secondary NCT02863328
  • -1.7 vs -0.9 14 mg · wk 26 · n 465 · Phase 3 · secondary NCT02607865
  • -2 vs -0.5 14 mg · wk 26 · n 294 · Phase 3 · secondary NCT04017832
  • -2.0 vs -2.1 14 mg · wk 52 · n 411 · Phase 3 · secondary NCT02863328
  • -1.8 vs -1.0 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -1.6 vs -0.9 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -1.2 vs -0.9 7 mg · wk 26 · n 465 · Phase 3 · secondary NCT02607865
  • -1.8 vs -0.5 7 mg · wk 26 · n 317 · Phase 3 · secondary NCT04017832
  • -1.3 vs -1.0 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -1.1 vs -0.9 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -0.8 vs -0.9 3 mg · wk 26 · n 466 · Phase 3 · secondary NCT02607865
  • -2.2 vs -1.8 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -2.0 vs -1.8 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -1.0 vs -0.5 3 mg · wk 26 · n 322 · Phase 3 · secondary NCT04017832
  • -1.0 vs -1.0 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -1.1 vs -0.9 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -2.7 vs -2.2 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -2.3 vs -2.2 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • -1.2 vs -2.2 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • -0.9 vs -1.8 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -2.4 vs -1.4 wk 52 · n 229 · Phase 3 · secondary NCT02849080
  • -0.3 vs 0.0 wk 104 · n 92 · Phase 3 · secondary NCT02849080

3-point MACE (% with event)

lixisenatide
—Not reported
Semaglutide (Rybelsus)
12% vs 13.8%−1.8 vs placebowk 265 · n 4825NCT03914326
1 other result
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
11 other shared endpoints and safety

Coverage. lixisenatide: 15 of 15 rows · Semaglutide (Rybelsus): 14 of 15 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metriclixisenatide
Rows use multiple source trials
Semaglutide (Rybelsus)
Rows use multiple source trials
Fasting Plasma Glucose
absolute change · mmol/L
No placebo or comparator arm
-0.57 mmol/L @ 24wka,b,c,d
NCT01517412 · Phase 3 · registry result, not featured evidence
show 1 more dose
-0.35 mmol/L @ 24wk
NCT01517412 · Phase 3 · registry result, not featured evidence
-39.4 mmol/L @ 104wkb,c,d
NCT02849080 · Phase 3 · registry result, not featured evidence
HbA1c
absolute change · percentage points
No placebo or comparator arm
-0.74% (n=222) @ 24wka,b,c,d
NCT01517412 · Phase 3 · registry result, not featured evidence
show 1 more dose
-0.65% (n=218) @ 24wk
NCT01517412 · Phase 3 · registry result, not featured evidence
-1.3% (n=180) @ 104wkb,c,d
NCT02849080 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7%
responder rate · % of participants
No placebo or comparator arm
40.6% (n=239) @ 24wka,b,c,e
NCT00712673 · Phase 3 · registry result, not featured evidence
show 1 more dose
43% (n=244) @ 24wk
NCT00712673 · Phase 3 · registry result, not featured evidence
39.2% (n=536) @ 68wk14 mg once dailya,b,c,e
NCT04707469 · Phase 3 · registry result, not featured evidence
show 2 more doses
58.9% (n=535) @ 68wk50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
49.9% (n=535) @ 68wk25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5
responder rate · % of participants
No placebo or comparator arm
19.2% (n=239) @ 24wka,b,c,e
NCT00712673 · Phase 3 · registry result, not featured evidence
show 1 more dose
23.8% (n=244) @ 24wk
NCT00712673 · Phase 3 · registry result, not featured evidence
23.6% (n=536) @ 68wk14 mg once dailya,b,c,e
NCT04707469 · Phase 3 · registry result, not featured evidence
show 2 more doses
46.2% (n=535) @ 68wk50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
35.8% (n=535) @ 68wk25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
PPG Excursion
absolute change · mmol/L
-3.42 vs -1.59 Insulin Glulisine mmol/L @ 26wkb,c
NCT01768559 · Phase 3 · registry result, not featured evidence
-1.2 vs -0.3 placebo mmol/L @ 26wk14 mga,b,c
NCT02906930 · Phase 3
show 2 more doses
-0.8 vs -0.3 placebo mmol/L @ 26wk7 mg
NCT02906930 · Phase 3
-0.4 vs -0.3 placebo mmol/L @ 26wk3 mg
NCT02906930 · Phase 3
PPG Excursion
absolute change · mg/dL
-70.43 vs -24.93 Liraglutide mg/dL @ 4wkf,b,c,g
NCT01175473 · Phase 2 · registry result, not featured evidence
-27.9 vs -6.7 placebo mg/dL @ 26wk14 mga,f,b,c,g
NCT04109547 · Phase 3 · registry result, not featured evidence
show 2 more doses
-20 vs -6.7 placebo mg/dL @ 26wk7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
-14.5 vs -6.7 placebo mg/dL @ 26wk3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
SMBG 7-point
absolute change · mmol/L
-0.784 vs -0.782 Insulin Glulisine mmol/L @ 26wkb,c
NCT01768559 · Phase 3 · registry result, not featured evidence
-2.3 vs -0.5 placebo mmol/L @ 26wk14 mga,b,c
NCT02906930 · Phase 3
show 2 more doses
-2.1 vs -0.5 placebo mmol/L @ 26wk7 mg
NCT02906930 · Phase 3
-1.8 vs -0.5 placebo mmol/L @ 26wk3 mg
NCT02906930 · Phase 3
TDDI Change Units Per
absolute change · per day
-1.39 vs -0.11 placebo per day @ 24wkb,c,h
NCT00866658 · Phase 3 · registry result, not featured evidence
-5 vs 8 placebo per day @ 52wk14 mga,b,c,h
NCT03021187 · Phase 3
show 2 more doses
-8 vs 8 placebo per day @ 52wk7 mg
NCT03021187 · Phase 3
1 vs 8 placebo per day @ 52wk3 mg
NCT03021187 · Phase 3
Waist Circumference Change
absolute change · cm
-1.4 vs -1.93 Liraglutide cm @ 8wk20 µgf,b,c,i
NCT01596504 · Phase 2 · registry result, not featured evidence
-1.8 vs -0.9 Sitagliptin cm @ 104wkf,b,c,i
NCT02849080 · Phase 3 · registry result, not featured evidence
Weight
absolute change · kg
No placebo or comparator arm
-2.8 kg @ 24wka,b,c,d
NCT01517412 · Phase 3 · registry result, not featured evidence
show 1 more dose
-2.6 kg @ 24wk
NCT01517412 · Phase 3 · registry result, not featured evidence
-3.7 kg @ 104wkb,c,d
NCT02849080 · Phase 3 · registry result, not featured evidence
Weight Loss 5%
responder rate · % of participants
No placebo or comparator arm
19.3% (n=249) @ 24wka,b,c,e
NCT00712673 · Phase 3 · registry result, not featured evidence
show 1 more dose
14.9% (n=248) @ 24wk
NCT00712673 · Phase 3 · registry result, not featured evidence
42.2% (n=536) @ 68wk14 mg once dailya,b,c,e
NCT04707469 · Phase 3 · registry result, not featured evidence
show 2 more doses
65.7% (n=535) @ 68wk50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
58.5% (n=535) @ 68wk25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
Dropout rate
32.5%j
NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 34 more results
9.2%Lixisenatide (One-Step Titration)
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
8.3%Lixisenatide (Two-Step Titration)
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
3.5%
NCT01147250 · Phase 3
11.3%
NCT05114590 · Phase 4 · registry result, not featured evidence
5.8%
NCT05413369 · Phase 3 · registry result, not featured evidence
—Fixed Ratio Combination
NCT02787551 · Phase 3 · registry result, not featured evidence
—Fixed Ratio Combination Whole Stud
NCT02787551 · Phase 3 · registry result, not featured evidence
10.5%Insulin Glargine/Lixisenatide Fixe
NCT02787551 · Phase 3 · registry result, not featured evidence
11.1%
NCT02168491 · Phase 3 · registry result, not featured evidence · combination
—
NCT02058160 · Phase 3 · registry result, not featured evidence
—Insulin Glargine/Lixisenatide Fixe
NCT02058147 · Phase 3 · registry result, not featured evidence
12.4%Lixisenatide
NCT02058147 · Phase 3 · registry result, not featured evidence
11.9%
NCT01798706 · Phase 3 · registry result, not featured evidence
10.1%
NCT01768559 · Phase 3 · registry result, not featured evidence
10.6%Lixisenatide Breakfast
NCT01517412 · Phase 3 · registry result, not featured evidence
16%Lixisenatide Main Meal
NCT01517412 · Phase 3 · registry result, not featured evidence
8.7%
NCT01169779 · Phase 3 · registry result, not featured evidence
13%
NCT00975286 · Phase 3 · registry result, not featured evidence
26%
NCT00763815 · Phase 3 · registry result, not featured evidence
27.5%Lixisenatide (Evening Injection)
NCT00712673 · Phase 3 · registry result, not featured evidence
22.4%Lixisenatide (Morning Injection)
NCT00712673 · Phase 3 · registry result, not featured evidence
10.1%
NCT00976937 · Phase 3 · registry result, not featured evidence
35.3%
NCT00715624 · Phase 3 · registry result, not featured evidence
30.9%
NCT00713830 · Phase 3 · registry result, not featured evidence
18.6%Lixisenatide (One-Step Titration)
NCT00763451 · Phase 3 · registry result, not featured evidence
24.8%Lixisenatide (Two-step Titration)
NCT00763451 · Phase 3 · registry result, not featured evidence
—Lixisenatide One-step Titration
NCT00763451 · Phase 3 · registry result, not featured evidence
25%Lixisenatide (One-step Titration)
NCT00905255 · Phase 3 · registry result, not featured evidence
39.4%Lixisenatide (Two-step Titration)
NCT00905255 · Phase 3 · registry result, not featured evidence
13.6%
NCT00866658 · Phase 3 · registry result, not featured evidence
—20 µg
NCT01596504 · Phase 2 · registry result, not featured evidence
4.2%20 μg
NCT01596504 · Phase 2 · registry result, not featured evidence
6.8%
NCT01476475 · Phase 2 · registry result, not featured evidence
2.6%
NCT01175473 · Phase 2 · registry result, not featured evidence
6.9%14 mgk
NCT02906930 · Phase 3
show 39 more results
8%7 mg
NCT02906930 · Phase 3
3.4%3 mg
NCT02906930 · Phase 3
2.7%14 mg
NCT02863328 · Phase 3
5.8%14 mg
NCT02607865 · Phase 3
6.4%7 mg
NCT02607865 · Phase 3
7.1%3 mg
NCT02607865 · Phase 3
2.8%14 mg
NCT02863419 · Phase 3
3.1%14 mg
NCT02827708 · Phase 3
3.3%14 mg
NCT03021187 · Phase 3
4.9%7 mg
NCT03021187 · Phase 3
5.4%3 mg
NCT03021187 · Phase 3
1.5%
NCT03914326 · Phase 3
0.3%
NCT02692716 · Phase 3
11.8%
NCT05035082 · Phase 4 · registry result, not featured evidence
5.4%14 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
5.6%50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
8.4%25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
7.2%14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
5%7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
4.4%3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
4.6%14 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
3.1%7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
3.1%3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Main Phase
NCT02849080 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Sustainabil
NCT02849080 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Switch
NCT02849080 · Phase 3 · registry result, not featured evidence
2.1%14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0%7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
6.1%3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
2.3%14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
1.5%7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
2.3%3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
11.3%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
11.4%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
5.7%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
7.1%20 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
2.9%10 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
8.6%5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
4.3%2.5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
14.1%j
NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 34 more results
2.5%Lixisenatide (One-Step Titration)
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
4.2%Lixisenatide (Two-Step Titration)
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
—
NCT01147250 · Phase 3
0.8%
NCT05114590 · Phase 4 · registry result, not featured evidence
0.3%
NCT05413369 · Phase 3 · registry result, not featured evidence
—Fixed Ratio Combination
NCT02787551 · Phase 3 · registry result, not featured evidence
—Fixed Ratio Combination Whole Stud
NCT02787551 · Phase 3 · registry result, not featured evidence
3.9%Insulin Glargine/Lixisenatide Fixe
NCT02787551 · Phase 3 · registry result, not featured evidence
—
NCT02168491 · Phase 3 · registry result, not featured evidence · combination
—
NCT02058160 · Phase 3 · registry result, not featured evidence
—Insulin Glargine/Lixisenatide Fixe
NCT02058147 · Phase 3 · registry result, not featured evidence
9%Lixisenatide
NCT02058147 · Phase 3 · registry result, not featured evidence
8.5%
NCT01798706 · Phase 3 · registry result, not featured evidence
5%
NCT01768559 · Phase 3 · registry result, not featured evidence
4.9%Lixisenatide Breakfast
NCT01517412 · Phase 3 · registry result, not featured evidence
4.4%Lixisenatide Main Meal
NCT01517412 · Phase 3 · registry result, not featured evidence
5.6%
NCT01169779 · Phase 3 · registry result, not featured evidence
8.5%
NCT00975286 · Phase 3 · registry result, not featured evidence
9%
NCT00763815 · Phase 3 · registry result, not featured evidence
10.2%Lixisenatide (Evening Injection)
NCT00712673 · Phase 3 · registry result, not featured evidence
8.2%Lixisenatide (Morning Injection)
NCT00712673 · Phase 3 · registry result, not featured evidence
2.5%
NCT00976937 · Phase 3 · registry result, not featured evidence
11.2%
NCT00715624 · Phase 3 · registry result, not featured evidence
12.4%
NCT00713830 · Phase 3 · registry result, not featured evidence
8.7%Lixisenatide (One-Step Titration)
NCT00763451 · Phase 3 · registry result, not featured evidence
11.8%Lixisenatide (Two-step Titration)
NCT00763451 · Phase 3 · registry result, not featured evidence
—Lixisenatide One-step Titration
NCT00763451 · Phase 3 · registry result, not featured evidence
13.9%Lixisenatide (One-step Titration)
NCT00905255 · Phase 3 · registry result, not featured evidence
21.2%Lixisenatide (Two-step Titration)
NCT00905255 · Phase 3 · registry result, not featured evidence
9.1%
NCT00866658 · Phase 3 · registry result, not featured evidence
—20 µg
NCT01596504 · Phase 2 · registry result, not featured evidence
2.1%20 μg
NCT01596504 · Phase 2 · registry result, not featured evidence
3.7%
NCT01476475 · Phase 2 · registry result, not featured evidence
2.6%
NCT01175473 · Phase 2 · registry result, not featured evidence
—14 mgk
NCT02906930 · Phase 3
show 39 more results
—7 mg
NCT02906930 · Phase 3
—3 mg
NCT02906930 · Phase 3
—14 mg
NCT02863328 · Phase 3
—14 mg
NCT02607865 · Phase 3
—7 mg
NCT02607865 · Phase 3
—3 mg
NCT02607865 · Phase 3
—14 mg
NCT02863419 · Phase 3
—14 mg
NCT02827708 · Phase 3
—14 mg
NCT03021187 · Phase 3
—7 mg
NCT03021187 · Phase 3
—3 mg
NCT03021187 · Phase 3
—
NCT03914326 · Phase 3
—
NCT02692716 · Phase 3
—
NCT05035082 · Phase 4 · registry result, not featured evidence
—14 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
—50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
—25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
—14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
—7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
—3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
—14 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
—7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
—3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Main Phase
NCT02849080 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Sustainabil
NCT02849080 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Switch
NCT02849080 · Phase 3 · registry result, not featured evidence
—14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
—7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
—3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
—14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
—7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
—3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
—40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—20 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—2.5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
Serious AEs
8.2%j
NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 34 more results
0%Lixisenatide (One-Step Titration)
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
0.8%Lixisenatide (Two-Step Titration)
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
20.6%
NCT01147250 · Phase 3
0.8%
NCT05114590 · Phase 4 · registry result, not featured evidence
5.2%
NCT05413369 · Phase 3 · registry result, not featured evidence
3.9%Fixed Ratio Combination
NCT02787551 · Phase 3 · registry result, not featured evidence
10.2%Fixed Ratio Combination Whole Stud
NCT02787551 · Phase 3 · registry result, not featured evidence
—Insulin Glargine/Lixisenatide Fixe
NCT02787551 · Phase 3 · registry result, not featured evidence
11.1%
NCT02168491 · Phase 3 · registry result, not featured evidence · combination
5.5%
NCT02058160 · Phase 3 · registry result, not featured evidence
3.8%Insulin Glargine/Lixisenatide Fixe
NCT02058147 · Phase 3 · registry result, not featured evidence
3.9%Lixisenatide
NCT02058147 · Phase 3 · registry result, not featured evidence
4.5%
NCT01798706 · Phase 3 · registry result, not featured evidence
3.7%
NCT01768559 · Phase 3 · registry result, not featured evidence
3.1%Lixisenatide Breakfast
NCT01517412 · Phase 3 · registry result, not featured evidence
3.1%Lixisenatide Main Meal
NCT01517412 · Phase 3 · registry result, not featured evidence
1.5%
NCT01169779 · Phase 3 · registry result, not featured evidence
7.6%
NCT00975286 · Phase 3 · registry result, not featured evidence
7.7%
NCT00763815 · Phase 3 · registry result, not featured evidence
10.2%Lixisenatide (Evening Injection)
NCT00712673 · Phase 3 · registry result, not featured evidence
8.2%Lixisenatide (Morning Injection)
NCT00712673 · Phase 3 · registry result, not featured evidence
1.9%
NCT00976937 · Phase 3 · registry result, not featured evidence
14%
NCT00715624 · Phase 3 · registry result, not featured evidence
10.1%
NCT00713830 · Phase 3 · registry result, not featured evidence
—Lixisenatide (One-Step Titration)
NCT00763451 · Phase 3 · registry result, not featured evidence
13%Lixisenatide (Two-step Titration)
NCT00763451 · Phase 3 · registry result, not featured evidence
9.9%Lixisenatide One-step Titration
NCT00763451 · Phase 3 · registry result, not featured evidence
2.8%Lixisenatide (One-step Titration)
NCT00905255 · Phase 3 · registry result, not featured evidence
6.1%Lixisenatide (Two-step Titration)
NCT00905255 · Phase 3 · registry result, not featured evidence
6.5%
NCT00866658 · Phase 3 · registry result, not featured evidence
2.1%20 µg
NCT01596504 · Phase 2 · registry result, not featured evidence
—20 μg
NCT01596504 · Phase 2 · registry result, not featured evidence
5.6%
NCT01476475 · Phase 2 · registry result, not featured evidence
0%
NCT01175473 · Phase 2 · registry result, not featured evidence
1.1%14 mgk
NCT02906930 · Phase 3
show 39 more results
1.7%7 mg
NCT02906930 · Phase 3
2.9%3 mg
NCT02906930 · Phase 3
6.6%14 mg
NCT02863328 · Phase 3
9.5%14 mg
NCT02607865 · Phase 3
10.1%7 mg
NCT02607865 · Phase 3
13.7%3 mg
NCT02607865 · Phase 3
10.9%14 mg
NCT02863419 · Phase 3
10.4%14 mg
NCT02827708 · Phase 3
6.6%14 mg
NCT03021187 · Phase 3
10.5%7 mg
NCT03021187 · Phase 3
13.6%3 mg
NCT03021187 · Phase 3
47.9%
NCT03914326 · Phase 3
18.9%
NCT02692716 · Phase 3
10.2%
NCT05035082 · Phase 4 · registry result, not featured evidence
9.9%14 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
8.2%50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
10.7%25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
3%14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
3.1%7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
4.4%3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
3.9%14 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
7.7%7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
4.6%3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
9.5%Oral Semaglutide Flex- Main Phase
NCT02849080 · Phase 3 · registry result, not featured evidence
14.2%Oral Semaglutide Flex- Sustainabil
NCT02849080 · Phase 3 · registry result, not featured evidence
9%Oral Semaglutide Flex- Switch
NCT02849080 · Phase 3 · registry result, not featured evidence
0%14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
6.1%7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
4.1%3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
5.4%14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
3%7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
6.9%3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
1.4%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
7.1%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
4.3%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
2.9%10 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
2.9%5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
1.4%2.5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
j
nausea 28.6%
nasopharyngitis 15.4%
diarrhoea 15.1%
NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 31 more results
nausea 20.2% (placebo 3.3%)
headache 7.6% (placebo 8.2%)
vomiting 6.7% (placebo 0%)
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
nausea 24.2% (placebo 3.3%)
headache 8.3% (placebo 8.2%)
dizziness 7.5% (placebo 3.3%)
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
nausea 21.7% (placebo 5.9%)
hypoglycaemia 20.1% (placebo 18.3%)
dizziness 8.5% (placebo 6.3%)
NCT01147250 · Phase 3
hypoglycaemia 5.7%
upper respiratory tract infection 5.7%
NCT05114590 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 17.2%
covid-19 13.4%
nausea 12.1%
NCT05413369 · Phase 3 · registry result, not featured evidence
nasopharyngitis 9.8%
nausea 8.6%
diarrhoea 5.5%
NCT02787551 · Phase 3 · registry result, not featured evidence
nasopharyngitis 15.5%
nausea 9.2%
diarrhoea 7.3%
NCT02787551 · Phase 3 · registry result, not featured evidence
mild asymptomatic hypoglycaemia 33.3%
hypercholesterolaemia 22.2%
mild gastrointestinal complaints 22.2%
NCT02168491 · Phase 3 · registry result, not featured evidence · combination
nausea 10.4%
nasopharyngitis 8.8%
headache 5.8%
NCT02058160 · Phase 3 · registry result, not featured evidence
nausea 9.6%
diarrhoea 9%
upper respiratory tract infection 7%
NCT02058147 · Phase 3 · registry result, not featured evidence
nausea 24%
diarrhoea 9%
headache 7.7%
NCT02058147 · Phase 3 · registry result, not featured evidence
nausea 25% (placebo 7.5%)
hypoglycaemia 17% (placebo 10.3%)
diarrhoea 10.8% (placebo 7.5%)
NCT01798706 · Phase 3 · registry result, not featured evidence
hypoglycaemia 35.9%
nausea 25.2%
blood glucose decreased 20.1%
NCT01768559 · Phase 3 · registry result, not featured evidence
nausea 15.5%
headache 7.1%
nasopharyngitis 7.1%
NCT01517412 · Phase 3 · registry result, not featured evidence
nausea 14.7%
nasopharyngitis 9.8%
hypoglycaemia 6.7%
NCT01517412 · Phase 3 · registry result, not featured evidence
nausea 16.3% (placebo 2.6%)
hypoglycaemia 9.2% (placebo 4.6%)
dizziness 8.7% (placebo 4.1%)
NCT01169779 · Phase 3 · registry result, not featured evidence
hypoglycaemia 27.4% (placebo 19.3%)
nausea 27.4% (placebo 4.9%)
headache 9.9% (placebo 3.6%)
NCT00975286 · Phase 3 · registry result, not featured evidence
nausea 26% (placebo 13.7%)
nasopharyngitis 16.4% (placebo 14.9%)
headache 13.3% (placebo 11.8%)
NCT00763815 · Phase 3 · registry result, not featured evidence
nausea 24.7% (placebo 10.6%)
headache 16.5% (placebo 23.5%)
vomiting 15.7% (placebo 3.5%)
NCT00712673 · Phase 3 · registry result, not featured evidence
nausea 25.1% (placebo 10.6%)
headache 19.2% (placebo 23.5%)
diarrhoea 15.3% (placebo 11.8%)
NCT00712673 · Phase 3 · registry result, not featured evidence
nausea 17.7%
headache 12.7%
diarrhoea 8.9%
NCT00976937 · Phase 3 · registry result, not featured evidence
hypoglycaemia 42.1% (placebo 40.7%)
nausea 29.3% (placebo 9.6%)
headache 12.5% (placebo 10.2%)
NCT00715624 · Phase 3 · registry result, not featured evidence
nausea 28% (placebo 8.8%)
hypoglycaemia 24.4% (placebo 19.3%)
nasopharyngitis 15.9% (placebo 20.4%)
NCT00713830 · Phase 3 · registry result, not featured evidence
nausea 37.9% (placebo 8.1%)
vomiting 18% (placebo 0.6%)
diarrhoea 14.9% (placebo 13.1%)
NCT00763451 · Phase 3 · registry result, not featured evidence
nausea 29.2% (placebo 8.1%)
vomiting 13% (placebo 0.6%)
headache 12.4% (placebo 12.5%)
NCT00763451 · Phase 3 · registry result, not featured evidence
nausea 50%
nasopharyngitis 36.1%
decreased appetite 19.4%
NCT00905255 · Phase 3 · registry result, not featured evidence
nausea 36.4%
nasopharyngitis 27.3%
decreased appetite 18.2%
NCT00905255 · Phase 3 · registry result, not featured evidence
hypoglycaemia 43.5% (placebo 23.6%)
nausea 39.6% (placebo 4.5%)
vomiting 18.2% (placebo 1.9%)
NCT00866658 · Phase 3 · registry result, not featured evidence
20 µg
decreased appetite 18.8%
nausea 18.8%
nasopharyngitis 12.5%
NCT01596504 · Phase 2 · registry result, not featured evidence
nausea 7.5%
nasopharyngitis 5.6%
headache 5%
NCT01476475 · Phase 2 · registry result, not featured evidence
nausea 22.1%
decreased appetite 18.2%
headache 11.7%
NCT01175473 · Phase 2 · registry result, not featured evidence
14 mgk
nausea 16% (placebo 5.6%)
vomiting 6.9% (placebo 2.2%)
decreased appetite 5.1% (placebo 0.6%)
NCT02906930 · Phase 3
show 38 more results
7 mg
nasopharyngitis 6.3% (placebo 3.4%)
headache 5.7% (placebo 5.1%)
diarrhoea 5.1% (placebo 2.2%)
NCT02906930 · Phase 3
3 mg
diarrhoea 8.6% (placebo 2.2%)
nausea 8% (placebo 5.6%)
nasopharyngitis 5.7% (placebo 3.4%)
NCT02906930 · Phase 3
14 mg
nausea 19.8%
diarrhoea 9.3%
vomiting 7.3%
NCT02863328 · Phase 3
14 mg
nausea 15.1%
diarrhoea 12%
nasopharyngitis 10.1%
NCT02607865 · Phase 3
7 mg
nausea 13.4%
diarrhoea 11.4%
nasopharyngitis 10.6%
NCT02607865 · Phase 3
3 mg
nasopharyngitis 11.4%
diarrhoea 9.4%
upper respiratory tract infection 7.7%
NCT02607865 · Phase 3
14 mg
nausea 19.3% (placebo 3.5%)
diarrhoea 15.1% (placebo 7.7%)
nasopharyngitis 14.4% (placebo 10.6%)
NCT02863419 · Phase 3
14 mg
nausea 19% (placebo 7.5%)
constipation 11.7% (placebo 3.7%)
vomiting 11.7% (placebo 1.2%)
NCT02827708 · Phase 3
14 mg
nausea 22.7% (placebo 7.1%)
diarrhoea 14.4% (placebo 6%)
decreased appetite 12.7% (placebo 1.1%)
NCT03021187 · Phase 3
7 mg
nausea 16.6% (placebo 7.1%)
diarrhoea 12.2% (placebo 6%)
nasopharyngitis 11.6% (placebo 14.7%)
NCT03021187 · Phase 3
3 mg
nasopharyngitis 14.7% (placebo 14.7%)
nausea 11.4% (placebo 7.1%)
diarrhoea 8.7% (placebo 6%)
NCT03021187 · Phase 3
diabetic retinopathy 19.5% (placebo 19.3%)
covid-19 15.7% (placebo 16.1%)
nausea 7.1% (placebo 1.3%)
NCT03914326 · Phase 3
covid-19 8.8%
nausea 7.6%
NCT05035082 · Phase 4 · registry result, not featured evidence
14 mg once daily
nausea 18%
diarrhoea 12.4%
covid-19 11.8%
NCT04707469 · Phase 3 · registry result, not featured evidence
50 mg once daily
nausea 27.3%
vomiting 18.2%
diarrhoea 14.2%
NCT04707469 · Phase 3 · registry result, not featured evidence
25 mg once daily
nausea 27.2%
vomiting 17%
diarrhoea 12.9%
NCT04707469 · Phase 3 · registry result, not featured evidence
14 mg
diarrhoea 13.3%
nausea 12.2%
decreased appetite 9.4%
NCT04017832 · Phase 3 · registry result, not featured evidence
7 mg
nausea 10.9%
diarrhoea 8.9%
decreased appetite 8.4%
NCT04017832 · Phase 3 · registry result, not featured evidence
3 mg
nausea 10%
diarrhoea 8.3%
upper respiratory tract infection 7.2%
NCT04017832 · Phase 3 · registry result, not featured evidence
14 mg
decreased appetite 10.9% (placebo 0%)
diarrhoea 9.3% (placebo 1.5%)
upper respiratory tract infection 7% (placebo 4.6%)
NCT04109547 · Phase 3 · registry result, not featured evidence
7 mg
diarrhoea 9.2% (placebo 1.5%)
upper respiratory tract infection 9.2% (placebo 4.6%)
lipase increased 8.5% (placebo 0%)
NCT04109547 · Phase 3 · registry result, not featured evidence
3 mg
upper respiratory tract infection 8.5% (placebo 4.6%)
lipase increased 5.4% (placebo 0%)
nausea 4.6% (placebo 1.5%)
NCT04109547 · Phase 3 · registry result, not featured evidence
nausea 20.9%
nasopharyngitis 10.3%
headache 9.9%
NCT02849080 · Phase 3 · registry result, not featured evidence
nausea 22.9%
nasopharyngitis 13.4%
diarrhoea 11.5%
NCT02849080 · Phase 3 · registry result, not featured evidence
nausea 17%
diarrhoea 10%
nasopharyngitis 7%
NCT02849080 · Phase 3 · registry result, not featured evidence
14 mg
nasopharyngitis 18.8% (placebo 28.6%)
constipation 12.5% (placebo 6.1%)
decreased appetite 12.5% (placebo 0%)
NCT03018028 · Phase 3 · registry result, not featured evidence
7 mg
nasopharyngitis 16.3% (placebo 28.6%)
constipation 12.2% (placebo 6.1%)
nausea 10.2% (placebo 2%)
NCT03018028 · Phase 3 · registry result, not featured evidence
3 mg
nasopharyngitis 20.4% (placebo 28.6%)
constipation 10.2% (placebo 6.1%)
periarthritis 10.2% (placebo 4.1%)
NCT03018028 · Phase 3 · registry result, not featured evidence
14 mg
nasopharyngitis 30%
constipation 15.4%
nausea 9.2%
NCT03015220 · Phase 3 · registry result, not featured evidence
7 mg
nasopharyngitis 29.5%
constipation 12.1%
decreased appetite 9.1%
NCT03015220 · Phase 3 · registry result, not featured evidence
3 mg
nasopharyngitis 26%
constipation 9.2%
influenza 6.9%
NCT03015220 · Phase 3 · registry result, not featured evidence
40 mg
nausea 33.8% (placebo 1.4%)
vomiting 19.7% (placebo 4.2%)
decreased appetite 14.1% (placebo 1.4%)
NCT01923181 · Phase 2 · registry result, not featured evidence
40 mg
nausea 35.7% (placebo 1.4%)
vomiting 22.9% (placebo 4.2%)
diarrhoea 17.1% (placebo 9.9%)
NCT01923181 · Phase 2 · registry result, not featured evidence
40 mg
nausea 32.9% (placebo 1.4%)
diarrhoea 20% (placebo 9.9%)
vomiting 15.7% (placebo 4.2%)
NCT01923181 · Phase 2 · registry result, not featured evidence
20 mg
nausea 35.7% (placebo 1.4%)
diarrhoea 20% (placebo 9.9%)
vomiting 17.1% (placebo 4.2%)
NCT01923181 · Phase 2 · registry result, not featured evidence
10 mg
nausea 33.3% (placebo 1.4%)
diarrhoea 23.2% (placebo 9.9%)
vomiting 20.3% (placebo 4.2%)
NCT01923181 · Phase 2 · registry result, not featured evidence
5 mg
nausea 14.3% (placebo 1.4%)
headache 12.9% (placebo 5.6%)
diarrhoea 10% (placebo 9.9%)
NCT01923181 · Phase 2 · registry result, not featured evidence
2.5 mg
nausea 12.9% (placebo 1.4%)
nasopharyngitis 8.6% (placebo 12.7%)
diarrhoea 7.1% (placebo 9.9%)
NCT01923181 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 24 weeks versus 104 weeks.
  5. eAssessment timepoints differ: 24 weeks versus 68 weeks.
  6. fTrial phases differ: Phase 2 versus Phase 3.
  7. gAssessment timepoints differ: 4 weeks versus 26 weeks.
  8. hAssessment timepoints differ: 24 weeks versus 52 weeks.
  9. iAssessment timepoints differ: 8 weeks versus 104 weeks.
  10. jPopulation comparability has not been reviewed for 32 of these studies.
  11. kPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

lixisenatide

HbA1c Less Than 7% 48.5% (n=295) vs 49.8% (n=297) Exenatide @ 24wk
responder rate · % of participants
NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 10 more results
72.5% (n=291) vs 59.8% (n=291) IDegAsp @ 24wk
NCT05413369 · Phase 3 · registry result, not featured evidence
53% (n=185) vs 38.8% (n=188) placebo @ 24wk
NCT01169779 · Phase 3 · registry result, not featured evidence
56.3% (n=215) vs 38.5% (n=221) placebo @ 24wk
NCT00975286 · Phase 3 · registry result, not featured evidence
52.3% (n=308) vs 26.4% (n=148) placebo @ 24wk
NCT00763815 · Phase 3 · registry result, not featured evidence
40.7% (n=150) vs 40% (n=160) Sitagliptin @ 24wk
NCT00976937 · Phase 3 · registry result, not featured evidence
28.3% (n=304) vs 12% (n=158) placebo @ 24wk
NCT00715624 · Phase 3 · registry result, not featured evidence
36.4% (n=544) vs 13.5% (n=274) placebo @ 24wk
NCT00713830 · Phase 3 · registry result, not featured evidence
42.1% (n=152) vs 24.1% (n=158) placebo @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
47.4% (n=156) vs 24.1% (n=158) placebo @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
35.6% (n=146) vs 5.2% (n=154) placebo @ 24wk
NCT00866658 · Phase 3 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5 28.5% (n=295) vs 35.4% (n=297) Exenatide @ 24wk
responder rate · % of participants
NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 9 more results
32.4% (n=185) vs 18.1% (n=188) placebo @ 24wk
NCT01169779 · Phase 3 · registry result, not featured evidence
32.1% (n=215) vs 16.3% (n=221) placebo @ 24wk
NCT00975286 · Phase 3 · registry result, not featured evidence
28.9% (n=308) vs 10.1% (n=148) placebo @ 24wk
NCT00763815 · Phase 3 · registry result, not featured evidence
24% (n=150) vs 26.3% (n=160) Sitagliptin @ 24wk
NCT00976937 · Phase 3 · registry result, not featured evidence
14.5% (n=304) vs 3.8% (n=158) placebo @ 24wk
NCT00715624 · Phase 3 · registry result, not featured evidence
19.3% (n=544) vs 4.7% (n=274) placebo @ 24wk
NCT00713830 · Phase 3 · registry result, not featured evidence
20.4% (n=152) vs 7.6% (n=158) placebo @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
25.6% (n=156) vs 7.6% (n=158) placebo @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
17.8% (n=146) vs 1.3% (n=154) placebo @ 24wk
NCT00866658 · Phase 3 · registry result, not featured evidence
Glycemic Rescue 2.2% (n=315) vs 3.8% (n=315) Exenatide @ 24wk
responder rate · % of participants
NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 15 more results
5.2% (n=291) vs 6.9% (n=291) IDegAsp @ 24wk
NCT05413369 · Phase 3 · registry result, not featured evidence
2.7% (n=366) vs 6% (n=365) Insulin Glargine
NCT02058160 · Phase 3 · registry result, not featured evidence
3.6% (n=468) vs 3.4% (n=466) Insulin Glargine @ 30wk
NCT02058147 · Phase 3 · registry result, not featured evidence
12.4% (n=233) vs 3.4% (n=466) Insulin Glargine @ 30wk
NCT02058147 · Phase 3 · registry result, not featured evidence
2.9% (n=175) vs 10.4% (n=173) placebo @ 24wk
NCT01798706 · Phase 3 · registry result, not featured evidence
3.6% (n=195) vs 6.7% (n=193) placebo @ 24wk
NCT01169779 · Phase 3 · registry result, not featured evidence
0.4% (n=223) vs 0.4% (n=223) placebo @ 24wk
NCT00975286 · Phase 3 · registry result, not featured evidence
3.8% (n=320) vs 11.3% (n=159) placebo @ 24wk
NCT00763815 · Phase 3 · registry result, not featured evidence
9.5% (n=158) vs 6.8% (n=161) Sitagliptin @ 24wk
NCT00976937 · Phase 3 · registry result, not featured evidence
5.8% (n=327) vs 7.2% (n=166) placebo @ 24wk
NCT00715624 · Phase 3 · registry result, not featured evidence
4% (n=570) vs 12.6% (n=286) placebo @ 24wk
NCT00713830 · Phase 3 · registry result, not featured evidence
3.1% (n=160) vs 4.4% (n=159) placebo @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
1.3% (n=160) vs 4.4% (n=159) placebo @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
1.3% (n=154) vs 3.2% (n=157) placebo @ 24wk
NCT00866658 · Phase 3 · registry result, not featured evidence
0% (n=161) vs 0.6% (n=162) Insulin Glargine @ 24wk
NCT01476475 · Phase 2 · registry result, not featured evidence
Weight Loss 5% 25.1% (n=295) vs 31.4% (n=296) Exenatide @ 24wk
responder rate · % of participants
NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 8 more results
19.7% (n=188) vs 14.7% (n=191) placebo @ 24wk
NCT01169779 · Phase 3 · registry result, not featured evidence
5.1% (n=217) vs 3.2% (n=220) placebo @ 24wk
NCT00975286 · Phase 3 · registry result, not featured evidence
9.2% (n=315) vs 5.1% (n=157) placebo @ 24wk
NCT00763815 · Phase 3 · registry result, not featured evidence
13.2% (n=311) vs 3.1% (n=161) placebo @ 24wk
NCT00715624 · Phase 3 · registry result, not featured evidence
14.4% (n=554) vs 7.2% (n=278) placebo @ 24wk
NCT00713830 · Phase 3 · registry result, not featured evidence
25.8% (n=155) vs 15.2% (n=158) placebo @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
19.6% (n=158) vs 15.2% (n=158) placebo @ 24wk
NCT00763451 · Phase 3 · registry result, not featured evidence
7.3% (n=150) vs 4.5% (n=157) placebo @ 24wk
NCT00866658 · Phase 3 · registry result, not featured evidence
PPG 2H -4.51 mmol/L @ 12wk
absolute change · mmol/L
No placebo or comparator arm
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
show 1 more result
-5.47 mmol/L @ 12wk
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
Glycemic Rescue 1.7% (n=120) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
show 3 more results
0.8% (n=118) @ 12wk
NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3
2.7% (n=255) @ 24wk
NCT00712673 · Phase 3 · registry result, not featured evidence
3.9% (n=255) @ 24wk
NCT00712673 · Phase 3 · registry result, not featured evidence
Time to First MACE 13.4% (n=3034) vs 13.2% (n=3034) placebo
event count · % of participants
NCT01147250 · Phase 3 · converted to % from 406 participants as posted
Time to Cardiovascular MACE 15% (n=3034) vs 15.5% (n=3034) placebo
event count · % of participants
NCT01147250 · Phase 3 · converted to % from 456 participants as posted
UACR 24.17% (n=2803) vs 34.21% (n=2830) placebo @ 108wk
percent change · % of baseline
NCT01147250 · Phase 3
Time in Range 24 h 26.22 % of time @ 16wk
absolute change · % of time
No placebo or comparator arm
NCT05114590 · Phase 4 · registry result, not featured evidence
Glucose Variability CV 5% (n=113) @ 16wk
absolute change · percentage points
No placebo or comparator arm
NCT05114590 · Phase 4 · registry result, not featured evidence
Daily Plasma Glucose Change mg/dL -2.91 mmol/L @ 16wk
absolute change · mmol/L
No placebo or comparator arm
NCT05114590 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -52.48 mg/dL as posted

+ 59 further endpoints in the CSV export.

Semaglutide (Rybelsus)

HbA1c -1.5% (n=175) vs -0.3% (n=178) placebo @ 26wk14 mg
absolute change · percentage points
In-trial
NCT02906930 · Phase 3
show 11 more results
-1.3% (n=411) vs -0.9% (n=410) Empagliflozin 25 mg @ 26wk14 mg
In-trial
NCT02863328 · Phase 3
-1.3% (n=465) vs -0.8% (n=467) Sitagliptin @ 26wk14 mg
In-trial
NCT02607865 · Phase 3
-1.2% (n=285) vs -0.1% (n=142) placebo @ 26wk14 mg
In-trial
NCT02863419 · Phase 3
-1.1% (n=163) vs -0.2% (n=161) placebo @ 26wk14 mg
In-trial
NCT02827708 · Phase 3
-1.3% (n=181) vs -0.1% (n=184) placebo @ 26wk14 mg
In-trial
NCT03021187 · Phase 3
-1.3% (n=175) vs -0.3% (n=178) placebo @ 26wk7 mg
In-trial
NCT02906930 · Phase 3
-1.1% (n=465) vs -0.8% (n=467) Sitagliptin @ 26wk7 mg
In-trial
NCT02607865 · Phase 3
-1% (n=182) vs -0.1% (n=184) placebo @ 26wk7 mg
In-trial
NCT03021187 · Phase 3
-0.9% (n=175) vs -0.3% (n=178) placebo @ 26wk3 mg
In-trial
NCT02906930 · Phase 3
-0.6% (n=466) vs -0.8% (n=467) Sitagliptin @ 26wk3 mg
In-trial
NCT02607865 · Phase 3
-0.5% (n=184) vs -0.1% (n=184) placebo @ 26wk3 mg
In-trial
NCT03021187 · Phase 3
Weight -4 vs -1.4 placebo kg @ 26wk14 mg
absolute change · kg
In-trial
NCT02906930 · Phase 3
show 9 more results
-3.9 vs -3.8 Empagliflozin 25 mg kg @ 26wk14 mg
In-trial
NCT02863328 · Phase 3
-3.1 vs -0.6 Sitagliptin kg @ 26wk14 mg
In-trial
NCT02607865 · Phase 3
-4.4 vs -0.6 placebo kg @ 26wk14 mg
In-trial
NCT02863419 · Phase 3
-3.5 vs -0.9 placebo kg @ 26wk14 mg
In-trial
NCT02827708 · Phase 3
-2.6 vs -1.4 placebo kg @ 26wk7 mg
In-trial
NCT02906930 · Phase 3
-2.2 vs -0.6 Sitagliptin kg @ 26wk7 mg
In-trial
NCT02607865 · Phase 3
-1.5 vs -1.4 placebo kg @ 26wk3 mg
In-trial
NCT02906930 · Phase 3
-1.2 vs -0.6 Sitagliptin kg @ 26wk3 mg
In-trial
NCT02607865 · Phase 3
-2.7 vs -0.7 Sitagliptin kg @ 52wk
In-trial
NCT02849080 · Phase 3 · registry result, not featured evidence
Weight -4.71% (n=160) vs -1.37% (n=168) placebo @ 26wk14 mg
percent change · % of baseline
NCT02906930 · Phase 3
show 43 more results
-4.34% (n=411) vs -4.14% (n=410) Empagliflozin 25 mg @ 26wk14 mg
NCT02863328 · Phase 3
-4.38% (n=411) vs -4.09% (n=410) Empagliflozin 25 mg @ 52wk14 mg
NCT02863328 · Phase 3
-3.44% (n=465) vs -0.64% (n=467) Sitagliptin @ 26wk14 mg
NCT02607865 · Phase 3
-3.83% (n=465) vs -0.76% (n=467) Sitagliptin @ 52wk14 mg
NCT02607865 · Phase 3
-3.47% (n=465) vs -0.99% (n=467) Sitagliptin @ 78wk14 mg
NCT02607865 · Phase 3
-4.89% (n=285) vs -0.6% (n=142) placebo @ 26wk14 mg
NCT02863419 · Phase 3
-4.94% (n=285) vs -0.99% (n=142) placebo @ 52wk14 mg
NCT02863419 · Phase 3
-3.75% (n=154) vs -0.92% (n=155) placebo @ 26wk14 mg
NCT02827708 · Phase 3
-4.3% (n=181) vs -0.47% (n=184) placebo @ 26wk14 mg
NCT03021187 · Phase 3
-4.42% (n=181) vs 0.65% (n=184) placebo @ 52wk14 mg
NCT03021187 · Phase 3
-5% (n=300) vs -1% (n=335) Sitagliptin @ 26wk14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-4% (n=116) vs -1% (n=106) placebo @ 26wk14 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
-3.54% (n=48) vs -1.58% (n=49) placebo @ 26wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-4.42% (n=48) vs -1.42% (n=49) placebo @ 52wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-3.21% (n=130) vs 0.25% (n=65) Dulaglutide @ 26wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-2.33% (n=130) vs 1.25% (n=65) Dulaglutide @ 52wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-2.85% (n=160) vs -1.37% (n=168) placebo @ 26wk7 mg
NCT02906930 · Phase 3
-2.36% (n=465) vs -0.64% (n=467) Sitagliptin @ 26wk7 mg
NCT02607865 · Phase 3
-2.63% (n=465) vs -0.76% (n=467) Sitagliptin @ 52wk7 mg
NCT02607865 · Phase 3
-2.92% (n=465) vs -0.99% (n=467) Sitagliptin @ 78wk7 mg
NCT02607865 · Phase 3
-3.11% (n=182) vs -0.47% (n=184) placebo @ 26wk7 mg
NCT03021187 · Phase 3
-2.54% (n=182) vs 0.65% (n=184) placebo @ 52wk7 mg
NCT03021187 · Phase 3
-4% (n=319) vs -1% (n=335) Sitagliptin @ 26wk7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-3% (n=119) vs -1% (n=106) placebo @ 26wk7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
-1.63% (n=49) vs -1.58% (n=49) placebo @ 26wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-1.23% (n=49) vs -1.42% (n=49) placebo @ 52wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-1.49% (n=132) vs 0.25% (n=65) Dulaglutide @ 26wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-1.34% (n=132) vs 1.25% (n=65) Dulaglutide @ 52wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-1.67% (n=168) vs -1.37% (n=168) placebo @ 26wk3 mg
NCT02906930 · Phase 3
-1.23% (n=466) vs -0.64% (n=467) Sitagliptin @ 26wk3 mg
NCT02607865 · Phase 3
-1.65% (n=466) vs -0.76% (n=467) Sitagliptin @ 52wk3 mg
NCT02607865 · Phase 3
-1.87% (n=466) vs -0.99% (n=467) Sitagliptin @ 78wk3 mg
NCT02607865 · Phase 3
-1.73% (n=184) vs -0.47% (n=184) placebo @ 26wk3 mg
NCT03021187 · Phase 3
-1.18% (n=184) vs 0.65% (n=184) placebo @ 52wk3 mg
NCT03021187 · Phase 3
-2% (n=322) vs -1% (n=335) Sitagliptin @ 26wk3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-1% (n=115) vs -1% (n=106) placebo @ 26wk3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
-0.64% (n=49) vs -1.58% (n=49) placebo @ 26wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.03% (n=49) vs -1.42% (n=49) placebo @ 52wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.28% (n=131) vs 0.25% (n=65) Dulaglutide @ 26wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.02% (n=131) vs 1.25% (n=65) Dulaglutide @ 52wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-4% (n=290) vs -3.53% (n=258) Other Oral Glucose-lowering Medication @ 52wk
NCT05035082 · Phase 4 · registry result, not featured evidence
-2.99% (n=233) vs -0.76% (n=239) Sitagliptin @ 52wk
NCT02849080 · Phase 3 · registry result, not featured evidence
-3.12% (n=93) vs -0.7% (n=97) Sitagliptin @ 104wk
NCT02849080 · Phase 3 · registry result, not featured evidence
BMI -1.5 vs -0.5 placebo kg @ 26wk14 mg
absolute change · kg
NCT02906930 · Phase 3
show 49 more results
-1.4 vs -1.4 Empagliflozin 25 mg kg @ 26wk14 mg
NCT02863328 · Phase 3
-1.5 vs -1.4 Empagliflozin 25 mg kg @ 52wk14 mg
NCT02863328 · Phase 3
-1.1 vs -0.2 Sitagliptin kg @ 26wk14 mg
NCT02607865 · Phase 3
-1.2 vs -0.3 Sitagliptin kg @ 52wk14 mg
NCT02607865 · Phase 3
-1.1 vs -0.4 Sitagliptin kg @ 78wk14 mg
NCT02607865 · Phase 3
-1.6 vs -0.2 placebo kg @ 26wk14 mg
NCT02863419 · Phase 3
-1.6 vs -0.4 placebo kg @ 52wk14 mg
NCT02863419 · Phase 3
-1.2 vs -0.3 placebo kg @ 26wk14 mg
NCT02827708 · Phase 3
-1.4 vs -0.2 placebo kg @ 26wk14 mg
NCT03021187 · Phase 3
-1.4 vs 0.2 placebo kg @ 52wk14 mg
NCT03021187 · Phase 3
-1.4 vs -0.2 Sitagliptin kg @ 26wk14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-1.1 vs -0.4 placebo kg @ 26wk14 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.4 placebo kg @ 26wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-1.1 vs -0.4 placebo kg @ 52wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.8 vs 0.1 Dulaglutide kg @ 26wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.6 vs 0.3 Dulaglutide kg @ 52wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.5 placebo kg @ 26wk7 mg
NCT02906930 · Phase 3
-0.8 vs -0.2 Sitagliptin kg @ 26wk7 mg
NCT02607865 · Phase 3
-0.9 vs -0.3 Sitagliptin kg @ 52wk7 mg
NCT02607865 · Phase 3
-1 vs -0.4 Sitagliptin kg @ 78wk7 mg
NCT02607865 · Phase 3
-1 vs -0.2 placebo kg @ 26wk7 mg
NCT03021187 · Phase 3
-0.8 vs 0.2 placebo kg @ 52wk7 mg
NCT03021187 · Phase 3
-1.1 vs -0.2 Sitagliptin kg @ 26wk7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-0.8 vs -0.4 placebo kg @ 26wk7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
-0.4 vs -0.4 placebo kg @ 26wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.3 vs -0.4 placebo kg @ 52wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.4 vs 0.1 Dulaglutide kg @ 26wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.3 vs 0.3 Dulaglutide kg @ 52wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.6 vs -0.5 placebo kg @ 26wk3 mg
NCT02906930 · Phase 3
-0.4 vs -0.2 Sitagliptin kg @ 26wk3 mg
NCT02607865 · Phase 3
-0.6 vs -0.3 Sitagliptin kg @ 52wk3 mg
NCT02607865 · Phase 3
-0.7 vs -0.4 Sitagliptin kg @ 78wk3 mg
NCT02607865 · Phase 3
-0.5 vs -0.2 placebo kg @ 26wk3 mg
NCT03021187 · Phase 3
-0.3 vs 0.2 placebo kg @ 52wk3 mg
NCT03021187 · Phase 3
-0.5 vs -0.2 Sitagliptin kg @ 26wk3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-0.4 vs -0.4 placebo kg @ 26wk3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
-0.1 vs -0.4 placebo kg @ 26wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0 vs -0.4 placebo kg @ 52wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.1 vs 0.1 Dulaglutide kg @ 26wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
0 vs 0.3 Dulaglutide kg @ 52wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-2.37 vs -0.43 placebo kg @ 26wk40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-2.04 vs -0.43 placebo kg @ 26wk40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-2.92 vs -0.43 placebo kg @ 26wk40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-1.93 vs -0.43 placebo kg @ 26wk20 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-1.72 vs -0.43 placebo kg @ 26wk10 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-0.98 vs -0.43 placebo kg @ 26wk5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-0.67 vs -0.43 placebo kg @ 26wk2.5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-1 vs -0.3 Sitagliptin kg @ 52wk
NCT02849080 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.3 Sitagliptin kg @ 104wk
NCT02849080 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7% 76.9% (n=160) vs 31% (n=168) placebo @ 26wk14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 123 Participants as posted
show 10 more results
57.8% (n=154) vs 22.6% (n=155) placebo @ 26wk*14 mg
Yes
NCT02827708 · Phase 3 · converted to % from 89 Participants as posted
75.8% (n=298) vs 36.5% (n=334) Sitagliptin @ 26wk*14 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 226 Participants as posted
79.3% (n=116) vs 25.5% (n=106) placebo @ 26wk*14 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 92 Participants as posted
68.8% (n=160) vs 31% (n=168) placebo @ 26wk*7 mg
Yes
NCT02906930 · Phase 3 · converted to % from 110 Participants as posted
67.6% (n=315) vs 36.5% (n=334) Sitagliptin @ 26wk*7 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 213 Participants as posted
85.5% (n=117) vs 25.5% (n=106) placebo @ 26wk*7 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 100 Participants as posted
55.1% (n=167) vs 31% (n=168) placebo @ 26wk*3 mg
Yes
NCT02906930 · Phase 3 · converted to % from 92 Participants as posted
43.3% (n=321) vs 36.5% (n=334) Sitagliptin @ 26wk*3 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 139 Participants as posted
65.8% (n=114) vs 25.5% (n=106) placebo @ 26wk*3 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 75 Participants as posted
58.3% (n=326) vs 45.4% (n=293) Other Oral Glucose-lowering Medication @ 52wk*
Yes
NCT05035082 · Phase 4 · registry result, not featured evidence · converted to % from 190 Participants as posted
HbA1c 6.5 or Less 63.8% (n=160) vs 17.9% (n=168) placebo @ 26wk14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 102 Participants as posted
show 2 more results
47.5% (n=160) vs 17.9% (n=168) placebo @ 26wk*7 mg
Yes
NCT02906930 · Phase 3 · converted to % from 76 Participants as posted
35.9% (n=167) vs 17.9% (n=168) placebo @ 26wk*3 mg
Yes
NCT02906930 · Phase 3 · converted to % from 60 Participants as posted
Weight Loss 5% 41.3% (n=160) vs 14.9% (n=168) placebo @ 26wk14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 66 Participants as posted
show 11 more results
35.7% (n=154) vs 9.7% (n=155) placebo @ 26wk*14 mg
Yes
NCT02827708 · Phase 3 · converted to % from 55 Participants as posted
44.7% (n=333) vs 8% (n=351) Sitagliptin @ 26wk*14 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 149 Participants as posted
37.1% (n=116) vs 10.4% (n=106) placebo @ 26wk*14 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 43 Participants as posted
26.9% (n=160) vs 14.9% (n=168) placebo @ 26wk*7 mg
Yes
NCT02906930 · Phase 3 · converted to % from 43 Participants as posted
31.3% (n=342) vs 8% (n=351) Sitagliptin @ 26wk*7 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 107 Participants as posted
24.4% (n=119) vs 10.4% (n=106) placebo @ 26wk*7 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 29 Participants as posted
19.6% (n=168) vs 14.9% (n=168) placebo @ 26wk*3 mg
Yes
NCT02906930 · Phase 3 · converted to % from 33 Participants as posted
16% (n=343) vs 8% (n=351) Sitagliptin @ 26wk*3 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 55 Participants as posted
14.8% (n=115) vs 10.4% (n=106) placebo @ 26wk*3 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 17 Participants as posted
36.9% (n=298) vs 31.9% (n=260) Other Oral Glucose-lowering Medication @ 52wk*
Yes
NCT05035082 · Phase 4 · registry result, not featured evidence · converted to % from 110 Participants as posted
27% (n=233) vs 12.1% (n=239) Sitagliptin @ 52wk*
Yes
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 63 Participants as posted
Weight Loss 10% 14.4% (n=160) vs 1.2% (n=168) placebo @ 26wk14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 23 Participants as posted
show 10 more results
8.4% (n=154) vs 0% (n=155) placebo @ 26wk*14 mg
Yes
NCT02827708 · Phase 3 · converted to % from 13 Participants as posted
12.6% (n=333) vs 0.6% (n=351) Sitagliptin @ 26wk*14 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 42 Participants as posted
10.3% (n=116) vs 0% (n=106) placebo @ 26wk*14 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 12 Participants as posted
8.1% (n=160) vs 1.2% (n=168) placebo @ 26wk*7 mg
Yes
NCT02906930 · Phase 3 · converted to % from 13 Participants as posted
7% (n=342) vs 0.6% (n=351) Sitagliptin @ 26wk*7 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 24 Participants as posted
5.9% (n=119) vs 0% (n=106) placebo @ 26wk*7 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 7 Participants as posted
2.4% (n=168) vs 1.2% (n=168) placebo @ 26wk*3 mg
Yes
NCT02906930 · Phase 3 · converted to % from 4 Participants as posted
1.5% (n=343) vs 0.6% (n=351) Sitagliptin @ 26wk*3 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 5 Participants as posted
4.3% (n=115) vs 0% (n=106) placebo @ 26wk*3 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 5 Participants as posted
6.4% (n=233) vs 2.1% (n=239) Sitagliptin @ 52wk*
Yes
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 15 Participants as posted
HbA1c Less Than 7 Without Hypoglycemia and no Weight Gain 68.8% (n=160) vs 23.2% (n=168) placebo @ 26wk14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 110 Participants as posted
show 10 more results
50.6% (n=154) vs 17.4% (n=155) placebo @ 26wk*14 mg
Yes
NCT02827708 · Phase 3 · converted to % from 78 Participants as posted
66.9% (n=332) vs 22.6% (n=350) Sitagliptin @ 26wk*14 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 222 Participants as posted
72.4% (n=116) vs 17.9% (n=106) placebo @ 26wk*14 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 84 Participants as posted
56.9% (n=160) vs 23.2% (n=168) placebo @ 26wk*7 mg
Yes
NCT02906930 · Phase 3 · converted to % from 91 Participants as posted
57.5% (n=339) vs 22.6% (n=350) Sitagliptin @ 26wk*7 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 195 Participants as posted
68.4% (n=117) vs 17.9% (n=106) placebo @ 26wk*7 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 80 Participants as posted
37.1% (n=167) vs 23.2% (n=168) placebo @ 26wk*3 mg
Yes
NCT02906930 · Phase 3 · converted to % from 62 Participants as posted
33.1% (n=344) vs 22.6% (n=350) Sitagliptin @ 26wk*3 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 114 Participants as posted
47.4% (n=114) vs 17.9% (n=106) placebo @ 26wk*3 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 54 Participants as posted
45.2% (n=230) vs 14.7% (n=238) Sitagliptin @ 52wk*
Yes
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 104 Participants as posted
HbA1c Reduction 1% and Weight Loss 3% 50.6% (n=160) vs 10.7% (n=168) placebo @ 26wk14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 81 Participants as posted
show 10 more results
39% (n=154) vs 7.7% (n=155) placebo @ 26wk*14 mg
Yes
NCT02827708 · Phase 3 · converted to % from 60 Participants as posted
47.9% (n=332) vs 9.4% (n=350) Sitagliptin @ 26wk*14 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 159 Participants as posted
45.7% (n=116) vs 9.4% (n=106) placebo @ 26wk*14 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 53 Participants as posted
36.9% (n=160) vs 10.7% (n=168) placebo @ 26wk*7 mg
Yes
NCT02906930 · Phase 3 · converted to % from 59 Participants as posted
37.8% (n=339) vs 9.4% (n=350) Sitagliptin @ 26wk*7 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 128 Participants as posted
36.8% (n=117) vs 9.4% (n=106) placebo @ 26wk*7 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 43 Participants as posted
18% (n=167) vs 10.7% (n=168) placebo @ 26wk*3 mg
Yes
NCT02906930 · Phase 3 · converted to % from 30 Participants as posted
18.6% (n=344) vs 9.4% (n=350) Sitagliptin @ 26wk*3 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 64 Participants as posted
22.8% (n=114) vs 9.4% (n=106) placebo @ 26wk*3 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 26 Participants as posted
34.8% (n=230) vs 10.5% (n=238) Sitagliptin @ 52wk*
Yes
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 80 Participants as posted
Time to Additional Anti-diabetic Medication 4% (n=175) vs 19.7% (n=178) placebo14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 7 Participants as posted
show 36 more results
4.1% (n=411) vs 3.2% (n=410) Empagliflozin 25 mg @ 26wk*14 mg
NCT02863328 · Phase 3 · converted to % from 17 Participants as posted
12.7% (n=411) vs 13.7% (n=410) Empagliflozin 25 mg @ 52wk*14 mg
NCT02863328 · Phase 3 · converted to % from 52 Participants as posted
3.2% (n=465) vs 4.3% (n=467) Sitagliptin @ 26wk*14 mg
NCT02607865 · Phase 3 · converted to % from 15 Participants as posted
11% (n=465) vs 23.8% (n=467) Sitagliptin @ 52wk*14 mg
NCT02607865 · Phase 3 · converted to % from 51 Participants as posted
16.1% (n=465) vs 31.7% (n=467) Sitagliptin @ 78wk*14 mg
NCT02607865 · Phase 3 · converted to % from 75 Participants as posted
7% (n=285) vs 8.5% (n=142) placebo @ 26wk*14 mg
NCT02863419 · Phase 3 · converted to % from 20 Participants as posted
13.7% (n=285) vs 32.4% (n=142) placebo @ 52wk*14 mg
NCT02863419 · Phase 3 · converted to % from 39 Participants as posted
7.4% (n=163) vs 13% (n=161) placebo*14 mg
NCT02827708 · Phase 3 · converted to % from 12 Participants as posted
4.4% (n=181) vs 6% (n=184) placebo @ 26wk*14 mg
NCT03021187 · Phase 3 · converted to % from 8 Participants as posted
24.3% (n=181) vs 40.8% (n=184) placebo @ 52wk*14 mg
NCT03021187 · Phase 3 · converted to % from 44 Participants as posted
2.1% (n=48) vs 14.3% (n=49) placebo @ 26wk*14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
8.3% (n=48) vs 30.6% (n=49) placebo @ 52wk*14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 4 Participants as posted
4.6% (n=130) vs 1.5% (n=65) Dulaglutide @ 26wk*14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 6 Participants as posted
6.2% (n=130) vs 12.3% (n=65) Dulaglutide @ 52wk*14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 8 Participants as posted
4.6% (n=175) vs 19.7% (n=178) placebo*7 mg
NCT02906930 · Phase 3 · converted to % from 8 Participants as posted
4.3% (n=465) vs 4.3% (n=467) Sitagliptin @ 26wk*7 mg
NCT02607865 · Phase 3 · converted to % from 20 Participants as posted
18.5% (n=465) vs 23.8% (n=467) Sitagliptin @ 52wk*7 mg
NCT02607865 · Phase 3 · converted to % from 86 Participants as posted
25.6% (n=465) vs 31.7% (n=467) Sitagliptin @ 78wk*7 mg
NCT02607865 · Phase 3 · converted to % from 119 Participants as posted
4.4% (n=182) vs 6% (n=184) placebo @ 26wk*7 mg
NCT03021187 · Phase 3 · converted to % from 8 Participants as posted
24.7% (n=182) vs 40.8% (n=184) placebo @ 52wk*7 mg
NCT03021187 · Phase 3 · converted to % from 45 Participants as posted
6.1% (n=49) vs 14.3% (n=49) placebo @ 26wk*7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 3 Participants as posted
12.2% (n=49) vs 30.6% (n=49) placebo @ 52wk*7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 6 Participants as posted
2.3% (n=132) vs 1.5% (n=65) Dulaglutide @ 26wk*7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 3 Participants as posted
9.8% (n=132) vs 12.3% (n=65) Dulaglutide @ 52wk*7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 13 Participants as posted
9.1% (n=175) vs 19.7% (n=178) placebo*3 mg
NCT02906930 · Phase 3 · converted to % from 16 Participants as posted
7.1% (n=466) vs 4.3% (n=467) Sitagliptin @ 26wk*3 mg
NCT02607865 · Phase 3 · converted to % from 33 Participants as posted
29.4% (n=466) vs 23.8% (n=467) Sitagliptin @ 52wk*3 mg
NCT02607865 · Phase 3 · converted to % from 137 Participants as posted
38.4% (n=466) vs 31.7% (n=467) Sitagliptin @ 78wk*3 mg
NCT02607865 · Phase 3 · converted to % from 179 Participants as posted
4.9% (n=184) vs 6% (n=184) placebo @ 26wk*3 mg
NCT03021187 · Phase 3 · converted to % from 9 Participants as posted
33.2% (n=184) vs 40.8% (n=184) placebo @ 52wk*3 mg
NCT03021187 · Phase 3 · converted to % from 61 Participants as posted
6.1% (n=49) vs 14.3% (n=49) placebo @ 26wk*3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 3 Participants as posted
16.3% (n=49) vs 30.6% (n=49) placebo @ 52wk*3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 8 Participants as posted
0.8% (n=131) vs 1.5% (n=65) Dulaglutide @ 26wk*3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
18.3% (n=131) vs 12.3% (n=65) Dulaglutide @ 52wk*3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 24 Participants as posted
8.7% (n=253) vs 18.7% (n=251) Sitagliptin*
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 22 Participants as posted
15% (n=100) vs 26.5% (n=98) Sitagliptin*
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 15 Participants as posted
Time to Rescue Medication 1.1% (n=175) vs 15.2% (n=178) placebo14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 2 Participants as posted
show 39 more results
1.9% (n=411) vs 1.2% (n=410) Empagliflozin 25 mg @ 26wk*14 mg
NCT02863328 · Phase 3 · converted to % from 8 Participants as posted
7.5% (n=411) vs 10.7% (n=410) Empagliflozin 25 mg @ 52wk*14 mg
NCT02863328 · Phase 3 · converted to % from 31 Participants as posted
1.1% (n=465) vs 2.8% (n=467) Sitagliptin @ 26wk*14 mg
NCT02607865 · Phase 3 · converted to % from 5 Participants as posted
6.7% (n=465) vs 20.1% (n=467) Sitagliptin @ 52wk*14 mg
NCT02607865 · Phase 3 · converted to % from 31 Participants as posted
10.1% (n=465) vs 27.6% (n=467) Sitagliptin @ 78wk*14 mg
NCT02607865 · Phase 3 · converted to % from 47 Participants as posted
3.5% (n=285) vs 7.7% (n=142) placebo @ 26wk*14 mg
NCT02863419 · Phase 3 · converted to % from 10 Participants as posted
7% (n=285) vs 30.3% (n=142) placebo @ 52wk*14 mg
NCT02863419 · Phase 3 · converted to % from 20 Participants as posted
4.3% (n=163) vs 9.9% (n=161) placebo*14 mg
NCT02827708 · Phase 3 · converted to % from 7 Participants as posted
2.2% (n=181) vs 4.9% (n=184) placebo @ 26wk*14 mg
NCT03021187 · Phase 3 · converted to % from 4 Participants as posted
17.1% (n=181) vs 36.4% (n=184) placebo @ 52wk*14 mg
NCT03021187 · Phase 3 · converted to % from 31 Participants as posted
1.7% (n=361) vs 1.9% (n=359) Sitagliptin*14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 6 Participants as posted
2.1% (n=48) vs 14.3% (n=49) placebo @ 26wk*14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
8.3% (n=48) vs 30.6% (n=49) placebo @ 52wk*14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 4 Participants as posted
0.8% (n=130) vs 1.5% (n=65) Dulaglutide @ 26wk*14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
1.5% (n=130) vs 9.2% (n=65) Dulaglutide @ 52wk*14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 2 Participants as posted
2.3% (n=175) vs 15.2% (n=178) placebo*7 mg
NCT02906930 · Phase 3 · converted to % from 4 Participants as posted
2.4% (n=465) vs 2.8% (n=467) Sitagliptin @ 26wk*7 mg
NCT02607865 · Phase 3 · converted to % from 11 Participants as posted
15.7% (n=465) vs 20.1% (n=467) Sitagliptin @ 52wk*7 mg
NCT02607865 · Phase 3 · converted to % from 73 Participants as posted
22.2% (n=465) vs 27.6% (n=467) Sitagliptin @ 78wk*7 mg
NCT02607865 · Phase 3 · converted to % from 103 Participants as posted
1.1% (n=182) vs 4.9% (n=184) placebo @ 26wk*7 mg
NCT03021187 · Phase 3 · converted to % from 2 Participants as posted
18.1% (n=182) vs 36.4% (n=184) placebo @ 52wk*7 mg
NCT03021187 · Phase 3 · converted to % from 33 Participants as posted
1.7% (n=360) vs 1.9% (n=359) Sitagliptin*7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 6 Participants as posted
4.1% (n=49) vs 14.3% (n=49) placebo @ 26wk*7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 2 Participants as posted
10.2% (n=49) vs 30.6% (n=49) placebo @ 52wk*7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 5 Participants as posted
0% (n=132) vs 1.5% (n=65) Dulaglutide @ 26wk*7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
6.1% (n=132) vs 9.2% (n=65) Dulaglutide @ 52wk*7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 8 Participants as posted
7.4% (n=175) vs 15.2% (n=178) placebo*3 mg
NCT02906930 · Phase 3 · converted to % from 13 Participants as posted
5.4% (n=466) vs 2.8% (n=467) Sitagliptin @ 26wk*3 mg
NCT02607865 · Phase 3 · converted to % from 25 Participants as posted
26% (n=466) vs 20.1% (n=467) Sitagliptin @ 52wk*3 mg
NCT02607865 · Phase 3 · converted to % from 121 Participants as posted
34.3% (n=466) vs 27.6% (n=467) Sitagliptin @ 78wk*3 mg
NCT02607865 · Phase 3 · converted to % from 160 Participants as posted
2.7% (n=184) vs 4.9% (n=184) placebo @ 26wk*3 mg
NCT03021187 · Phase 3 · converted to % from 5 Participants as posted
29.3% (n=184) vs 36.4% (n=184) placebo @ 52wk*3 mg
NCT03021187 · Phase 3 · converted to % from 54 Participants as posted
1.4% (n=361) vs 1.9% (n=359) Sitagliptin*3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 5 Participants as posted
4.1% (n=49) vs 14.3% (n=49) placebo @ 26wk*3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 2 Participants as posted
14.3% (n=49) vs 30.6% (n=49) placebo @ 52wk*3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence · converted to % from 7 Participants as posted
0% (n=131) vs 1.5% (n=65) Dulaglutide @ 26wk*3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
16.8% (n=131) vs 9.2% (n=65) Dulaglutide @ 52wk*3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence · converted to % from 22 Participants as posted
3.2% (n=253) vs 15.9% (n=251) Sitagliptin*
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 8 Participants as posted
9% (n=100) vs 23.5% (n=98) Sitagliptin*
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 9 Participants as posted

+ 114 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: lixisenatide's landscape · Semaglutide (Rybelsus)'s landscape